4. REFERENCES
1.Radmayr, C., et al. EAU Guidelines on Paediatric Urology, in EAU Guidelines, Edn. presented at the 41st EAU Annual Congress London. 2026.
https://uroweb.org/guidelines/paediatric-urology
2.Blok, B., et al. EAU Guidelines on Neuro-urology, in EAU Guidelines, Edn. presented at the 41st EAU Annual Congress London. 2026.
https://uroweb.org/guideline/neuro-urology/
3.Phillips B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
4.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://www.ncbi.nlm.nih.gov/pubmed/18467413
5.Horan, T.C., et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008. 36: 309.
https://www.ncbi.nlm.nih.gov/pubmed/18538699
6.Rubin, R.H., et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis, 1992. 15 Suppl 1: S216.
https://www.ncbi.nlm.nih.gov/pubmed/1477233
7.Rubin, R.H., et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of urinary tract infection. The European Society of Clinical Microbiology and Infectious diseases. Taukirchen, Germany., 1993: 240.
8.U.S. Department of Health and Human Services. FDA Center for Drug Evaluation and Research Guidance for Industry Uncomplicated Urinary Tract Infections - Developing Antimicrobial Drugs for Treatment. 2015.
https://www.fda.gov/media/129531/download
9.U.S. Department of Health and Human Services. FDA Center for Drug Evaluation and Research Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry 2018.
https://www.fda.gov/media/71313/download
10.Bell, B.G., et al. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis, 2014. 14: 13.
https://www.ncbi.nlm.nih.gov/pubmed/24405683
11.World Health Organization. Antimicrobial resistance: global report on surveillance 2014. 2014.
https://www.who.int/publications/i/item/9789241564748
12.Hulscher, M.E., et al. Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis, 2010. 10: 167.
https://www.ncbi.nlm.nih.gov/pubmed/20185095
13.Goff, D.A., et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis, 2017. 17: e56.
https://www.ncbi.nlm.nih.gov/pubmed/27866945
14.Dellit, T.H., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis, 2007. 44: 159.
https://www.ncbi.nlm.nih.gov/pubmed/17173212
15.Davey, P., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev, 2017. 2: CD003543.
https://www.ncbi.nlm.nih.gov/pubmed/28178770
16.Cefai, C., et al. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use. NICE Guidelines, 2015.
https://www.nice.org.uk/guidance/ng15
17.Schuts, E.C., et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis, 2016. 16: 847.
https://www.ncbi.nlm.nih.gov/pubmed/26947617
18.Hermanides, H.S., et al. Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care. Clin Infect Dis, 2008. 46: 703.
https://www.ncbi.nlm.nih.gov/pubmed/18230045
19.Spoorenberg, V., et al. Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis, 2014. 58: 164.
https://www.ncbi.nlm.nih.gov/pubmed/24158412
20.Lutay, N., et al. Bacterial control of host gene expression through RNA polymerase II. J Clin Invest, 2013. 123: 2366.
https://www.ncbi.nlm.nih.gov/pubmed/23728172
21.Hansson, S., et al. Untreated asymptomatic bacteriuria in girls: II--Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections. BMJ, 1989. 298: 856.
https://www.ncbi.nlm.nih.gov/pubmed/2497823
22.Cai, T., et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis, 2012. 55: 771.
https://www.ncbi.nlm.nih.gov/pubmed/22677710
23.Nicolle, L.E., et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis, 2005. 40: 643.
https://www.ncbi.nlm.nih.gov/pubmed/15714408
24.Kass, E.H. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians, 1956. 69: 56.
https://www.ncbi.nlm.nih.gov/pubmed/13380946
25.Gleckman, R., et al. Reliability of a single urine culture in establishing diagnosis of asymptomatic bacteriuria in adult males. J Clin Microbiol, 1979. 9: 596.
https://www.ncbi.nlm.nih.gov/pubmed/383746
26.Kunin CM. Urinary tract infections: detection, prevention and management 5th ed. Baltimore: Williams and Wilkins, 1997.
https://link.springer.com/article/10.1007/BF02771849
27.Warren, J.W., et al. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis, 1982. 146: 719.
https://www.ncbi.nlm.nih.gov/pubmed/6815281
28.Hooton, T.M., et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis, 2010. 50: 625.
https://www.ncbi.nlm.nih.gov/pubmed/20175247
29.Koves, B., et al. Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur Urol, 2017. 72: 865.
https://www.ncbi.nlm.nih.gov/pubmed/28754533
30.Tencer, J. Asymptomatic bacteriuria--a long-term study. Scand J Urol Nephrol, 1988. 22: 31.
https://www.ncbi.nlm.nih.gov/pubmed/3387908
31.Asscher, A.W., et al. The clinical significance of asymptomatic bacteriuria in the nonpregnant woman. J Infect Dis, 1969. 120: 17.
https://www.ncbi.nlm.nih.gov/pubmed/5803281
32.Elder, H.A., et al. The natural history of asymptomatic bacteriuria during pregnancy: the effect of tetracycline on the clinical course and the outcome of pregnancy. Am J Obstet Gynecol, 1971. 111: 441.
https://www.ncbi.nlm.nih.gov/pubmed/4937729
33.Elder, H.A., et al. Use of sulfasymazine in the treatment of bacteriuria of pregnancy. Antimicrob Agents Chemother (Bethesda), 1966. 6: 142.
https://www.ncbi.nlm.nih.gov/pubmed/4862162
34.Gold, E.M., et al. Asymptomatic bacteriuria during pregnancy. Obstet Gynecol, 1966. 27: 206.
https://www.ncbi.nlm.nih.gov/pubmed/5325600
35.Kass, E.H. Pyelonephritis and bacteriuria. A major problem in preventive medicine. Ann Intern Med, 1962. 56: 46.
https://www.ncbi.nlm.nih.gov/pubmed/14454174
36.Kincaid-Smith, P., et al. Bacteriuria in Pregnancy. Lancet, 1965. 1: 395.
https://www.ncbi.nlm.nih.gov/pubmed/14238090
37.Little, P.J. The incidence of urinary infection in 5000 pregnant women. Lancet, 1966. 2: 925.
https://www.ncbi.nlm.nih.gov/pubmed/4162367
38.Mulla, N. Bacteriuria in pregnancy. Obstet Gynecol, 1960. 16: 89.
https://www.ncbi.nlm.nih.gov/pubmed/14425118
39.Pathak, U.N., et al. Bacteriuria of pregnancy: results of treatment. J Infect Dis, 1969. 120: 91.
https://www.ncbi.nlm.nih.gov/pubmed/5816817
40.Robertson, J.G., et al. The managment and complications of asymptomatic bacteriuria in pregnancy. Report of a study on 8,275 patients. J Obstet Gynaecol Br Commonw, 1968. 75: 59.
https://www.ncbi.nlm.nih.gov/pubmed/5635245
41.Thomsen, A.C., et al. Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour. Lancet, 1987. 1: 591.
https://www.ncbi.nlm.nih.gov/pubmed/2881132
42.Williams, G.L., et al. Urinary concentrating ability in women with asymptomatic bacteriuria in pregnancy. Br Med J, 1969. 3: 212.
https://www.ncbi.nlm.nih.gov/pubmed/5792611
43.Wren, B.G. Subclinical renal infection and prematurity. Med J Aust, 1969. 2: 596.
https://www.ncbi.nlm.nih.gov/pubmed/5388374
44.Kazemier, B.M., et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis, 2015. 15: 1324.
https://www.ncbi.nlm.nih.gov/pubmed/26255208
45.Henderson, J.T., et al. Screening for Asymptomatic Bacteriuria in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2019. 322: 1195.
https://www.ncbi.nlm.nih.gov/pubmed/31550037
46.Smaill, F.M., et al. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev, 2019. 2019: CD000490.
https://www.ncbi.nlm.nih.gov/pubmed/31765489
47.Wingert, A., et al. Asymptomatic bacteriuria in pregnancy: systematic reviews of screening and treatment effectiveness and patient preferences. BMJ Open, 2019. 9: e021347.
https://www.ncbi.nlm.nih.gov/pubmed/30872538
48.Christopher, L.J., et al. A trial of hippramine in the treatment of bacteriuria of pregnancy. Ir J Med Sci, 1969. 8: 331.
https://www.ncbi.nlm.nih.gov/pubmed/5806178
49.Reeves, D.S. Laboratory and clinical studies with sulfametopyrazine as a treatment for bacteriuria in pregnancy. J Antimicrob Chemother, 1975. 1: 171.
https://www.ncbi.nlm.nih.gov/pubmed/1100589
50.Whalley, P.J., et al. Short-term versus continuous antimicrobial therapy for asymptomatic bacteriuria in pregnancy. Obstet Gynecol, 1977. 49: 262.
https://www.ncbi.nlm.nih.gov/pubmed/320525
51.Bint, A., et al. A comparative trial of pivmecillinam and ampicillin in bacteriuria of pregnancy. Infection, 1979. 7: 290.
https://www.ncbi.nlm.nih.gov/pubmed/232697
52.Harris, R.E., et al. Single-dose antimicrobial therapy for asymptomatic bacteriuria during pregnancy. Obstet Gynecol, 1982. 59: 546.
https://www.ncbi.nlm.nih.gov/pubmed/7070725
53.Bailey, R.R., et al. Comparison of single dose with a 5-day course of co-trimoxazole for asymptomatic (covert) bacteriuria of pregnancy. Aust N Z J Obstet Gynaecol, 1983. 23: 139.
https://www.ncbi.nlm.nih.gov/pubmed/6606421
54.Masterton, R.G., et al. Single-dose amoxycillin in the treatment of bacteriuria in pregnancy and the puerperium--a controlled clinical trial. Br J Obstet Gynaecol, 1985. 92: 498.
https://www.ncbi.nlm.nih.gov/pubmed/3888250
55.Pedler, S.J., et al. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother, 1985. 27: 508.
https://www.ncbi.nlm.nih.gov/pubmed/4004191
56.Campbell-Brown, M., et al. Is screening for bacteriuria in pregnancy worth while? Br Med J (Clin Res Ed), 1987. 294: 1579.
https://www.ncbi.nlm.nih.gov/pubmed/3113538
57.Pregazzi, R., et al. [Single-dose antibiotic therapy of asymptomatic bacteriuria in pregnancy. Results and complications]. Minerva Ginecol, 1987. 39: 289.
https://www.ncbi.nlm.nih.gov/pubmed/3601207
58.Gerstner, G.J., et al. Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy: a single dose of 3 g amoxicillin versus a 4-day course of 3 doses 750 mg amoxicillin. Gynecol Obstet Invest, 1989. 27: 84.
https://www.ncbi.nlm.nih.gov/pubmed/2659442
59.Olsen, L., et al. Single-dose versus six-day therapy with sulfamethizole for asymptomatic bacteriuria during pregnancy. A prospective randomised study. Dan Med Bull, 1989. 36: 486.
https://www.ncbi.nlm.nih.gov/pubmed/2680315
60.Thoumsin, H., et al. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. Infection, 1990. 18 Suppl 2: S94.
https://www.ncbi.nlm.nih.gov/pubmed/2286469
61.Bayrak, O., et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy? Int Urogynecol J Pelvic Floor Dysfunct, 2007. 18: 525.
https://www.ncbi.nlm.nih.gov/pubmed/16941068
62.Estebanez, A., et al. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis, 2009. 28: 1457.
https://www.ncbi.nlm.nih.gov/pubmed/19768649
63.Lumbiganon, P., et al. One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: a randomized controlled trial. Obstet Gynecol, 2009. 113: 339.
https://www.ncbi.nlm.nih.gov/pubmed/19155904
64.Widmer, M., et al. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev, 2015. 2015: CD000491.
https://www.ncbi.nlm.nih.gov/pubmed/26560337
65.Wang, T., et al. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and meta-analysis. Int J Antimicrob Agents, 2020. 56: 106018.
https://www.ncbi.nlm.nih.gov/pubmed/32417205
66.Zhanel, G.G., et al. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis, 1991. 13: 150.
https://www.ncbi.nlm.nih.gov/pubmed/2017615
67.Harding, G.K., et al. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med, 2002. 347: 1576.
https://www.ncbi.nlm.nih.gov/pubmed/12432044
68.Mody, L., et al. Urinary tract infections in older women: a clinical review. JAMA, 2014. 311: 844.
https://www.ncbi.nlm.nih.gov/pubmed/24570248
69.Boscia, J.A., et al. Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. JAMA, 1987. 257: 1067.
https://www.ncbi.nlm.nih.gov/pubmed/3806896
70.Abrutyn, E., et al. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Intern Med, 1994. 120: 827.
https://www.ncbi.nlm.nih.gov/pubmed/7818631
71.Abrutyn, E., et al. Does treatment of asymptomatic bacteriuria in older ambulatory women reduce subsequent symptoms of urinary tract infection? J Am Geriatr Soc, 1996. 44: 293.
https://www.ncbi.nlm.nih.gov/pubmed/8600199
72.Nicolle, L.E., et al. Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women. Am J Med, 1987. 83: 27.
https://www.ncbi.nlm.nih.gov/pubmed/3300325
73.Nicolle, L.E. Asymptomatic bacteriuria in the elderly. Infect Dis Clin North Am, 1997. 11: 647.
https://www.ncbi.nlm.nih.gov/pubmed/9378928
74.Silver, S.A., et al. Positive urine cultures: A major cause of inappropriate antimicrobial use in hospitals? Can J Infect Dis Med Microbiol, 2009. 20: 107.
https://www.ncbi.nlm.nih.gov/pubmed/21119801
75.Trautner, B.W. Asymptomatic bacteriuria: when the treatment is worse than the disease. Nat Rev Urol, 2011. 9: 85.
https://www.ncbi.nlm.nih.gov/pubmed/22143416
76.Nicolle, L.E., et al. Bacteriuria in elderly institutionalized men. N Engl J Med, 1983. 309: 1420.
https://www.ncbi.nlm.nih.gov/pubmed/6633618
77.Potts, L., et al. A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria. Arch Gerontol Geriatr, 1996. 23: 153.
https://www.ncbi.nlm.nih.gov/pubmed/15374159
78.Renneberg, J., et al. Single-day treatment with trimethoprim for asymptomatic bacteriuria in the elderly patient. J Urol, 1984. 132: 934.
https://www.ncbi.nlm.nih.gov/pubmed/6387184
79.Ouslander, J.G., et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med, 1995. 122: 749.
https://www.ncbi.nlm.nih.gov/pubmed/7717597
80.Krzyzaniak, N., et al. Antibiotics versus no treatment for asymptomatic bacteriuria in residents of aged care facilities: a systematic review and meta-analysis. Br J Gen Pract, 2022. 72: e649.
https://www.ncbi.nlm.nih.gov/pubmed/35940886
81.Moradi, M., et al. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J, 2005. 2: 32.
https://www.ncbi.nlm.nih.gov/pubmed/17629893
82.El Amari, E.B., et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant, 2011. 26: 4109.
https://www.ncbi.nlm.nih.gov/pubmed/21592976
83.Green, H., et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis, 2013. 32: 127.
https://www.ncbi.nlm.nih.gov/pubmed/22918514
84.Origuen, J., et al. Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial. Am J Transplant, 2016. 16: 2943.
https://www.ncbi.nlm.nih.gov/pubmed/27088545
85.Antonio, M.E.E., et al. Treatment of asymptomatic bacteriuria in the first 2 months after kidney transplant: A controlled clinical trial. Transpl Infect Dis, 2022. 24: e13934.
https://www.ncbi.nlm.nih.gov/pubmed/35980169
86.Sabe, N., et al. Antibiotic Treatment Versus No Treatment for Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Multicenter Randomized Trial. Open Forum Infect Dis, 2019. 6: ofz243.
https://www.ncbi.nlm.nih.gov/pubmed/31214630
87.Arencibia, N., et al. Short-Term Outcome of Untreated Versus Treated Asymptomatic Bacteriuria in Renal Transplant Patients. Transplant Proc, 2016. 48: 2941.
https://www.ncbi.nlm.nih.gov/pubmed/27932112
88.Coussement, J., et al. Antibiotics for asymptomatic bacteriuria in kidney transplant recipients. Cochrane Database Syst Rev, 2018. 2: CD011357.
https://www.ncbi.nlm.nih.gov/pubmed/29390169
89.Gomez-Ochoa, S.A., et al. Systematic review and meta-analysis of asymptomatic bacteriuria after renal transplantation: incidence, risk of complications, and treatment outcomes. Transpl Infect Dis, 2020. 22: e13221.
https://www.ncbi.nlm.nih.gov/pubmed/31782870
90.Nicolle, L.E. Urinary tract infections in patients with spinal injuries. Curr Infect Dis Rep, 2014. 16: 390.
https://www.ncbi.nlm.nih.gov/pubmed/24445675
91.Wullt, B., et al. Bladder, bowel and bugs--bacteriuria in patients with intestinal urinary diversion. World J Urol, 2004. 22: 186.
https://www.ncbi.nlm.nih.gov/pubmed/15309491
92.Qu, L.G., et al. Systematic review: bacterial colonisation of conduits and neobladders-when to test, watch, and treat. World J Urol, 2020. 38: 1413.
https://www.ncbi.nlm.nih.gov/pubmed/31560122
93.Darouiche, R.O., et al. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis, 2005. 41: 1531.
https://www.ncbi.nlm.nih.gov/pubmed/16231269
94.Sunden, F., et al. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol, 2010. 184: 179.
https://www.ncbi.nlm.nih.gov/pubmed/20483149
95.Bonkat, G., et al. Microbial biofilm formation and catheter-associated bacteriuria in patients with suprapubic catheterisation. World J Urol, 2013. 31: 565.
https://www.ncbi.nlm.nih.gov/pubmed/22926265
96.Tenke, P., et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents, 2008. 31 Suppl 1: S68.
https://www.ncbi.nlm.nih.gov/pubmed/18006279
97.Cooper, F.P., et al. Policies for replacing long-term indwelling urinary catheters in adults. Cochrane Database Syst Rev, 2016. 7: CD011115.
https://www.ncbi.nlm.nih.gov/pubmed/27457774
98.Dasgupta, R., et al. Preoperative antibiotics before endourologic surgery: current recommendations. J Endourol, 2009. 23: 1567.
https://www.ncbi.nlm.nih.gov/pubmed/19785548
99.Grabe, M., et al. The effect of a short antibiotic course in transurethral prostatic resection. Scand J Urol Nephrol, 1984. 18: 37.
https://www.ncbi.nlm.nih.gov/pubmed/6202000
100.Grabe, M., et al. Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. Eur J Clin Microbiol, 1987. 6: 11.
https://www.ncbi.nlm.nih.gov/pubmed/3569248
101.Cafferkey, M.T., et al. Antibiotics for the prevention of septicaemia in urology. J Antimicrob Chemother, 1982. 9: 471.
https://www.ncbi.nlm.nih.gov/pubmed/7107549
102.Murphy, D.M., et al. Bacteraemia during prostatectomy and other transurethral operations: influence of timing of antibiotic administration. J Clin Pathol, 1984. 37: 673.
https://www.ncbi.nlm.nih.gov/pubmed/6725613
103.Chong, J.T., et al. Pre-procedural antibiotics for endoscopic urological procedures: Initial experience in individuals with spinal cord injury and asymptomatic bacteriuria. J Spinal Cord Med, 2015. 38: 187.
https://www.ncbi.nlm.nih.gov/pubmed/24621035
104.Cordero-Ampuero, J., et al. Are antibiotics necessary in hip arthroplasty with asymptomatic bacteriuria? Seeding risk with/without treatment. Clin Orthop Relat Res, 2013. 471: 3822.
https://www.ncbi.nlm.nih.gov/pubmed/23430723
105.Sousa, R., et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? Clin Infect Dis, 2014. 59: 41.
https://www.ncbi.nlm.nih.gov/pubmed/24723280
106.Rodriguez-Pardo, D., et al. Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial. Eur J Clin Microbiol Infect Dis, 2021. 40: 2411.
https://www.ncbi.nlm.nih.gov/pubmed/33864153
107.Gómez-Ochoa, S.A., et al. Risk of Surgical Site Infection in Patients with Asymptomatic Bacteriuria or Abnormal Urinalysis before Joint Arthroplasty: Systematic Review and Meta-Analysis. Surgical Infections, 2019. 20: 159.
https://www.ncbi.nlm.nih.gov/pubmed/30688601
108.Jami, S.A., et al. The necessity of treating asymptomatic bacteriuria with antibiotics in the perioperative period of joint arthroplasty: a metaanalysis. Turk J Med Sci, 2021. 51: 464.
https://www.ncbi.nlm.nih.gov/pubmed/33021755
109.Sousa, R.J.G., et al. Is Routine Urinary Screening Indicated Prior To Elective Total Joint Arthroplasty? A Systematic Review and Meta-Analysis. J Arthroplasty, 2019. 34: 1523.
https://www.ncbi.nlm.nih.gov/pubmed/30956050
110.Wang, C., et al. Current evidence does not support systematic antibiotherapy prior to joint arthroplasty in patients with asymptomatic bacteriuria-a meta analysis. Int Orthop, 2018. 42: 479.
https://www.ncbi.nlm.nih.gov/pubmed/29368046
111.Gomez-Ochoa, S.A., et al. Lack of Benefit on Treating Asymptomatic Bacteriuria Prior to Cardiovascular Surgery: a Systematic Review and Meta-Analysis. Braz J Cardiovasc Surg, 2018. 33: 641.
https://www.ncbi.nlm.nih.gov/pubmed/30652758
112.Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon, 2003. 49: 53.
https://www.ncbi.nlm.nih.gov/pubmed/12601337
113.Wagenlehner, F.M., et al. Uncomplicated urinary tract infections. Dtsch Arztebl Int, 2011. 108: 415.
https://www.ncbi.nlm.nih.gov/pubmed/21776311
114.Stamm, W.E., et al. Management of urinary tract infections in adults. N Engl J Med, 1993. 329: 1328.
https://www.ncbi.nlm.nih.gov/pubmed/8413414
115.Foxman, B., et al. Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol, 2001. 54: 710.
https://www.ncbi.nlm.nih.gov/pubmed/11438412
116.van Buul, L.W., et al. The Development of a Decision Tool for the Empiric Treatment of Suspected Urinary Tract Infection in Frail Older Adults: A Delphi Consensus Procedure. J Am Med Dir Assoc, 2018. 19: 757.
https://www.ncbi.nlm.nih.gov/pubmed/29910137
117.Bent, S., et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA, 2002. 287: 2701.
https://www.ncbi.nlm.nih.gov/pubmed/12020306
118.Bradbury, S.M. Collection of urine specimens in general practice: to clean or not to clean? J R Coll Gen Pract, 1988. 38: 363.
https://www.ncbi.nlm.nih.gov/pubmed/3256648
119.Lifshitz, E., et al. Outpatient urine culture: does collection technique matter? Arch Intern Med, 2000. 160: 2537.
https://www.ncbi.nlm.nih.gov/pubmed/10979067
120.Fihn, S.D. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med, 2003. 349: 259.
https://www.ncbi.nlm.nih.gov/pubmed/12867610
121.Foxman, B., et al. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am, 2003. 17: 227.
https://www.ncbi.nlm.nih.gov/pubmed/12848468
122.Gbinigie, O.A., et al. Cranberry Extract for Symptoms of Acute, Uncomplicated Urinary Tract Infection: A Systematic Review. Antibiotics (Basel), 2020. 10.
https://www.ncbi.nlm.nih.gov/pubmed/33375566
123.Barbosa-Cesnik, C., et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis, 2011. 52: 23.
https://www.ncbi.nlm.nih.gov/pubmed/21148516
124.Little, P., et al. Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technol Assess, 2009.
13: iii.
https://www.ncbi.nlm.nih.gov/pubmed/19364448
125.Sengupta, K., et al. A Randomized, Double Blind, Controlled, Dose Dependent Clinical Trial to Evaluate the Efficacy of a Proanthocyanidin Standardized Whole Cranberry (Vaccinium macrocarpon) Powder on Infections of the Urinary Tract. Current Bioactive Compounds, 2011. 7: 39.
http://www.eurekaselect.com/article/18604
126.Parazzini, F., et al. Systematic review of the effect of D-mannose with or without other drugs in the treatment of symptoms of urinary tract infections/cystitis (Review). Biomed Rep, 2022. 17: 69.
https://pubmed.ncbi.nlm.nih.gov/35815191
127.Rădulescu, D., et al. Combination of cranberry extract and D-mannose - possible enhancer of uropathogen sensitivity to antibiotics in acute therapy of urinary tract infections: Results of a pilot study. Exp Ther Med, 2020. 20: 3399.
https://www.ncbi.nlm.nih.gov/pubmed/32905041
128.Porru, D., et al. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. Journal of Clinical Urology, 2014. 7: 208.
https://doi.org/10.1177/2051415813518332
129.Domenici, L., et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci, 2016. 20: 2920.
https://www.ncbi.nlm.nih.gov/pubmed/27424995
130.Salvatore, S., et al. A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections. Eur Urol Focus, 2023. 9: 654.
https://www.ncbi.nlm.nih.gov/pubmed/36621376
131.Wagenlehner, F.M., et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int, 2018. 101: 327.
https://www.ncbi.nlm.nih.gov/pubmed/30231252
132.Cai, T., et al. L-Methionine associated with Hibiscus sabdariffa and Boswellia serrata extracts are not inferior to antibiotic treatment for symptoms relief in patients affected by recurrent uncomplicated urinary tract infections: Focus on antibiotic-sparing approach. Arch Ital Urol Androl, 2018. 90: 97.
https://www.ncbi.nlm.nih.gov/pubmed/29974725
133.van Wietmarschen, H., et al. Effectiveness of herbal medicines to prevent and control symptoms of urinary tract infections and to reduce antibiotic use: A literature review. Integr Med Res, 2022. 11: 100892.
https://www.ncbi.nlm.nih.gov/pubmed/36345487
134.Costache, R.C., et al. Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults. Urol Int, 2019. 102: 468.
https://www.ncbi.nlm.nih.gov/pubmed/30889607
135.Cai, T., et al. Xyloglucan, Hibiscus and Propolis in the Management of Uncomplicated Lower Urinary Tract Infections: A Systematic Review and Meta-Analysis. Antibiotics (Basel), 2021. 11.
https://www.ncbi.nlm.nih.gov/pubmed/35052890
136.Kaußner, Y., et al. Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. Clin Microbiol Infect, 2022. 28: 1558.
https://pubmed.ncbi.nlm.nih.gov/35788049
137.Ong Lopez, A.M.C., et al. Symptomatic treatment (using NSAIDS) versus antibiotics in uncomplicated lower urinary tract infection: a meta-analysis and systematic review of randomized controlled trials. BMC Infect Dis, 2021. 21: 619.
https://www.ncbi.nlm.nih.gov/pubmed/34187385
138.Bleidorn, J., et al. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? - Results of a randomized controlled pilot trial. BMC Medicine, 2010. 8: 30.
https://pubmed.ncbi.nlm.nih.gov/20504298/
139.Gágyor, I., et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. Bmj, 2015. 351: h6544.
https://pubmed.ncbi.nlm.nih.gov/26698878
140.Vik, I., et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med, 2018. 15: e1002569.
https://pubmed.ncbi.nlm.nih.gov/29763434
141.Kronenberg, A., et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. Bmj, 2017. 359: j4784.
https://pubmed.ncbi.nlm.nih.gov/29113968
142.Gágyor, I., et al. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clin Microbiol Infect, 2021. 27: 1441.
https://pubmed.ncbi.nlm.nih.gov/34111592
143.Mann, N.K., et al. Potentially Inadequate Medications in the Elderly: PRISCUS 2.0. Dtsch Arztebl Int, 2023. 120: 3.
https://pubmed.ncbi.nlm.nih.gov/36507719
144.Falagas, M.E., et al. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect, 2009. 58: 91.
https://www.ncbi.nlm.nih.gov/pubmed/19195714
145.e.V., D.G.f.U., S3 Leitlinie: Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei Erwachsenen - Aktualisierung 2024. 2024.
https://register.awmf.org/de/leitlinien/detail/043-044
146.Gupta, K., et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med, 2007. 167: 2207.
https://www.ncbi.nlm.nih.gov/pubmed/17998493
147.Lecomte, F., et al. Single-dose treatment of cystitis with fosfomycin trometamol (Monuril): analysis of 15 comparative trials on 2,048 patients. . Giorn It Ost Gin, 1997. 19: 399.
https://www.sciencedirect.com/science/article/pii/S0399077X96802095
148.Nicolle, L.E. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother, 2000. 46 Suppl 1: 35.
https://www.ncbi.nlm.nih.gov/pubmed/11051622
149.Huttner, A., et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother, 2015. 70: 2456.
https://www.ncbi.nlm.nih.gov/pubmed/26066581
150.Gupta, K., et al. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents, 2002. 19: 554.
https://www.ncbi.nlm.nih.gov/pubmed/12135847
151.Warren, J.W., et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis, 1999. 29: 745.
https://www.ncbi.nlm.nih.gov/pubmed/10589881
152.Hooton, T.M., et al. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA, 2012. 307: 583.
https://www.ncbi.nlm.nih.gov/pubmed/22318279
153.Hooton, T.M., et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA, 2005. 293: 949.
https://www.ncbi.nlm.nih.gov/pubmed/15728165
154.European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Quinolone and fluoroquinolone Article-31 referral, 2019.
https://www.ema.europa.eu/en/news/disabling-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-fluoroquinolone-antibiotics
155.Vazquez, J.C., et al. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev, 2000: CD002256.
https://www.ncbi.nlm.nih.gov/pubmed/10908537
156.Geerts, A.F., et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol, 2013. 69: 1701.
https://www.ncbi.nlm.nih.gov/pubmed/23660771
157.German Society of Urology. 3 guideline: epidemiology, diagnosis, treatment, prevention and management of uncomplicated, bacterial, community-acquired urinary tract infections in adults - update 2024. 2024.
https://register.awmf.org/de/leitlinien/detail/043-044
158.Hooton, T.M. Recurrent urinary tract infection in women. Int J Antimicrob Agents, 2001. 17: 259.
https://www.ncbi.nlm.nih.gov/pubmed/11295405
159.Naber, K.G., et al. Psychosocial burden of recurrent uncomplicated urinary tract infections. GMS Infect Dis, 2022. 10: Doc01.
https://www.ncbi.nlm.nih.gov/pubmed/35463815
160.van Haarst, E.P., et al. Evaluation of the diagnostic workup in young women referred for recurrent lower urinary tract infections. Urology, 2001. 57: 1068.
https://www.ncbi.nlm.nih.gov/pubmed/11377307
161.Hooton, T.M., Prevention of recurrent urogenital tract infections in adult women, in EAU/International Consultation on Urological Infections. T, K.G. Naber, A.J. Schaeffer, C.F. Hynes & e. al., Editors. 2010, European Association of Urology: The Netherlands.
http://www.icud.info/urogenitalinfections.html
162.Cai, T., et al. Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference. Eur Urol Focus, 2022. 8: 1476.
https://www.ncbi.nlm.nih.gov/pubmed/35135727
163.Adatto, K., et al. Behavioral factors and urinary tract infection. JAMA, 1979. 241: 2525.
https://www.ncbi.nlm.nih.gov/pubmed/439337
164.Lumsden, L., et al. Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients. Women Health, 1985. 10: 79.
https://www.ncbi.nlm.nih.gov/pubmed/3984360
165.Hooton, T.M., et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med, 2018. 178: 1509.
https://www.ncbi.nlm.nih.gov/pubmed/30285042
166.Chen, Y.Y., et al. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J, 2021. 32: 17.
https://www.ncbi.nlm.nih.gov/pubmed/32564121
167.Beerepoot, M.A., et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol, 2013. 190: 1981.
https://www.ncbi.nlm.nih.gov/pubmed/23867306
168.Leckie, K.J. What is the evidence for the role of oestrogen in the prevention of recurrent urinary tract infections in postmenopausal women? An evidence-based review. J Clin Gerontol Geriatr, 2010. 1: 31.
https://www.sciencedirect.com/science/article/pii/S2210833510000298
169.Duenas-Garcia, O.F., et al. Pharmacological Agents to Decrease New Episodes of Recurrent Lower Urinary Tract Infections in Postmenopausal Women. A Systematic Review. Female Pelvic Med Reconstr Surg, 2016. 22: 63.
https://www.ncbi.nlm.nih.gov/pubmed/26825411
170.Pinggera, G.M., et al. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives. Eur Urol, 2005. 47: 243.
https://www.ncbi.nlm.nih.gov/pubmed/15661421
171.Mak, Q., et al. Bacterial Vaccines for the Management of Recurrent Urinary Tract Infections: A Systematic Review and Meta-analysis. Eur Urol Focus, 2024. 10: 761.
https://www.ncbi.nlm.nih.gov/pubmed/38644097
172.Kranz, J., et al. Current Evidence on Nonantibiotic Prevention of Recurrent Urinary Tract Infections. Eur Urol Focus, 2019. 5: 17.
https://www.ncbi.nlm.nih.gov/pubmed/30292420
173.Abad, C.L., et al. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review. J Chemother, 2009. 21: 243.
https://www.ncbi.nlm.nih.gov/pubmed/19567343
174.Canales, J., et al. Are probiotics effective in preventing urinary tract infection? Medwave, 2018. 18: e7186.
https://www.ncbi.nlm.nih.gov/pubmed/29624569
175.Falagas, M.E., et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs, 2006. 66: 1253.
https://www.ncbi.nlm.nih.gov/pubmed/16827601
176.Grin, P.M., et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol, 2013. 20: 6607.
https://www.ncbi.nlm.nih.gov/pubmed/23433130
177.Hanson, L., et al. Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review. J Midwifery Womens Health, 2016. 61: 339.
https://www.ncbi.nlm.nih.gov/pubmed/27218592
178.Ng, Q.X., et al. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Med Hypotheses, 2018. 114: 49.
https://www.ncbi.nlm.nih.gov/pubmed/29602464
179.Akgul, T., et al. The role of probiotics in women with recurrent urinary tract infections. Turk J Urol, 2018. 44: 377.
https://www.ncbi.nlm.nih.gov/pubmed/30487041
180.Andreu, A. Lactobacillus as a probiotic for preventing urogenital infections. Reviews in Medical Microbiology, 2004. 15: 1.
https://www.researchgate.net/publication/232117977
181.Barrons, R., et al. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther, 2008. 30: 453.
https://www.ncbi.nlm.nih.gov/pubmed/18405785
182.Hoesl, C.E., et al. The probiotic approach: an alternative treatment option in urology. Eur Urol, 2005. 47: 288.
https://www.ncbi.nlm.nih.gov/pubmed/15716188
183.Ray, K. Infection: Lactobacillus probiotic could prevent recurrent UTI. Nat Rev Urol, 2011. 8: 292.
https://www.ncbi.nlm.nih.gov/pubmed/21660070
184.Reid, G., et al. Probiotics to prevent urinary tract infections: the rationale and evidence. World J Urol, 2006. 24: 28.
https://www.ncbi.nlm.nih.gov/pubmed/16389539
185.Abdullatif, V.A., et al. Efficacy of Probiotics as Prophylaxis for Urinary Tract Infections in Premenopausal Women: A Systematic Review and Meta-Analysis. Cureus, 2021. 13: e18843.
https://www.ncbi.nlm.nih.gov/pubmed/34671514
186.Naber, K.G., et al. Therapeutic strategies for uncomplicated cystitis in women. GMS Infect Dis, 2024. 12: Doc01.
https://www.ncbi.nlm.nih.gov/pubmed/38764941
187.Sabadash, M., et al. Canephron® N in the treatment of recurrent cystitis in women of child-bearing Age: a randomised controlled study. Clinical Phytoscience, 2017. 3: 9.
https://clinphytoscience.springeropen.com/articles/10.1186/s40816-017-0046-7
188.Hudson, R.E., et al. Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. Front Pharmacol, 2022. 13: 883216.
https://www.ncbi.nlm.nih.gov/pubmed/35571128
189.Jepson, R.G., et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev, 2012. 10: CD001321.
https://www.ncbi.nlm.nih.gov/pubmed/23076891
190.Fu, Z., et al. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr, 2017. 147: 2282.
https://www.ncbi.nlm.nih.gov/pubmed/29046404
191.Luis, A., et al. Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials. J Urol, 2017. 198: 614.
https://www.ncbi.nlm.nih.gov/pubmed/28288837
192.Wang, C.H., et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med, 2012. 172: 988.
https://www.ncbi.nlm.nih.gov/pubmed/22777630
193.Tambunan, M.P., et al. Cranberries for women with recurrent urinary tract infection: a meta-analysis. Medical Journal of Indonesia, 2019. 28: 268.
https://mji.ui.ac.id/journal/index.php/mji/article/view/3299
194.Xia, J.Y., et al. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One, 2021. 16: e0256992.
https://www.ncbi.nlm.nih.gov/pubmed/34473789
195.Liska, D.J., et al. Cranberries and Urinary Tract Infections: How Can the Same Evidence Lead to Conflicting Advice? Adv Nutr, 2016. 7: 498.
https://www.ncbi.nlm.nih.gov/pubmed/27184277
196.Babar, A., et al. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol, 2021. 21: 44.
https://www.ncbi.nlm.nih.gov/pubmed/33757474
197.Rondanelli, M., et al. Supplementation with Highly Standardized Cranberry Extract Phytosome Achieved the Modulation of Urinary Tract Infection Episodes in Diabetic Postmenopausal Women Taking SGLT-2 Inhibitors: A RCT Study. Nutrients, 2024. 16.
https://pubmed.ncbi.nlm.nih.gov/38999860
198.Tsiakoulias, E., et al. Randomized, placebo-controlled, double-blinded study of prophylactic cranberries use in women with recurrent uncomplicated cystitis. World J Urol, 2024. 42: 27.
https://pubmed.ncbi.nlm.nih.gov/38214795
199.Moro, C., et al. Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. European Urology Focus, 2024.
https://pubmed.ncbi.nlm.nih.gov/39030132/
200.Lenger, S.M., et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol, 2020. 223: 265 e1.
https://www.ncbi.nlm.nih.gov/pubmed/32497610
201.Kyriakides, R., et al. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus, 2021. 7: 1166.
https://www.ncbi.nlm.nih.gov/pubmed/32972899
202.Cooper, T.E., et al. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev, 2022. 8: CD013608.
https://www.ncbi.nlm.nih.gov/pubmed/36041061
203.Hayward, G., et al. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. JAMA Internal Medicine, 2024. 184: 619.
https://doi.org/10.1001/jamainternmed.2024.0264
204.Damiano, R., et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol, 2011. 59: 645.
https://www.ncbi.nlm.nih.gov/pubmed/21272992
205.De Vita, D., et al. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J, 2012. 23: 1707.
https://www.ncbi.nlm.nih.gov/pubmed/22614285
206.Goddard, J.C., et al. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J, 2018. 29: 933.
https://www.ncbi.nlm.nih.gov/pubmed/29181550
207.Lee, B.S., et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev, 2012. 10: CD003265.
https://www.ncbi.nlm.nih.gov/pubmed/23076896
208.Bakhit, M., et al. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. Br J Gen Pract, 2021. 71: e528.
https://www.ncbi.nlm.nih.gov/pubmed/34001538
209.Harding, C., et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technol Assess, 2022. 26: 1.
https://www.ncbi.nlm.nih.gov/pubmed/35535708
210.Harding, C., et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ, 2022. 376: e068229.
https://www.ncbi.nlm.nih.gov/pubmed/35264408
211.Nalliah, S., et al. The use of chemotherapeutic agents as prophylaxis for recurrent urinary tract infection in healthy nonpregnant women: A network meta-analysis. Indian J Urol, 2019. 35: 147.
https://www.ncbi.nlm.nih.gov/pubmed/31000921
212.Ahmed, H., et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open, 2017. 7: e015233.
https://www.ncbi.nlm.nih.gov/pubmed/28554926
213.Price, J.R., et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol, 2016. 215: 548.
https://www.ncbi.nlm.nih.gov/pubmed/27457111
214.Albert, X., et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev, 2004. 2004: CD001209.
https://www.ncbi.nlm.nih.gov/pubmed/15266443
215.Eells, S.J., et al. Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis, 2014. 58: 147.
https://www.ncbi.nlm.nih.gov/pubmed/24065333
216.Anger, J., et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol, 2019. 202: 282.
https://www.ncbi.nlm.nih.gov/pubmed/31042112
217.Kranz, J., et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int, 2018. 100: 271.
https://www.ncbi.nlm.nih.gov/pubmed/29539622
218.Epp, A., et al. No. 250-Recurrent Urinary Tract Infection. J Obstet Gynaecol Can, 2017. 39: e422.
https://www.ncbi.nlm.nih.gov/pubmed/28935065
219.Lichtenberger, P., et al. Antimicrobial prophylaxis in women with recurrent urinary tract infections. Int J Antimicrob Agents, 2011. 38 Suppl: 36.
https://www.ncbi.nlm.nih.gov/pubmed/22055655
220.Sen, A. Recurrent cystitis in non-pregnant women. BMJ Clin Evid, 2008. 2008.
https://www.ncbi.nlm.nih.gov/pubmed/19445741
221.Chew, L.D., et al. Recurrent cystitis in nonpregnant women. West J Med, 1999. 170: 274.
https://www.ncbi.nlm.nih.gov/pubmed/10379218
222.Rudenko, N., et al. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung, 2005. 55: 420.
https://www.ncbi.nlm.nih.gov/pubmed/16080282
223.Costantini, E., et al. Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial. Int Urogynecol J, 2014. 25: 1173.
https://pubmed.ncbi.nlm.nih.gov/24554302
224.Pfau, A., et al. Effective prophylaxis for recurrent urinary tract infections during pregnancy. Clin Infect Dis, 1992. 14: 810.
https://www.ncbi.nlm.nih.gov/pubmed/1576275
225.Schaeffer, A.J., et al. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol, 1999. 161: 207.
https://www.ncbi.nlm.nih.gov/pubmed/10037399
226.Scholes, D., et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med, 2005. 142: 20.
https://www.ncbi.nlm.nih.gov/pubmed/15630106
227.Hill, J.B., et al. Acute pyelonephritis in pregnancy. Obstet Gynecol, 2005. 105: 18.
https://www.ncbi.nlm.nih.gov/pubmed/15625136
228.Fulop, T. Acute Pyelonephritis Workup. 2012.
http://emedicine.medscape.com/article/245559-workup#aw2aab6b5b3
229.van Nieuwkoop, C., et al. Predicting the need for radiologic imaging in adults with febrile urinary tract infection. Clin Infect Dis, 2010. 51: 1266.
https://www.ncbi.nlm.nih.gov/pubmed/21034195
230.Cattrall, J.W.S., et al. A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis, 2018. 37: 2285.
https://www.ncbi.nlm.nih.gov/pubmed/30191339
231.Gupta, K., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 2011. 52: e103.
https://www.ncbi.nlm.nih.gov/pubmed/21292654
232.Berti, F., et al. Short versus long course antibiotic therapy for acute pyelonephritis in adults: a systematic review and meta-analysis. Italian Journal of Medicine, 2018. 12: 39.
https://www.italjmed.org/index.php/ijm/article/view/itjm.2018.840
233.Hooton, T.M. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med, 2012. 366: 1028.
https://www.ncbi.nlm.nih.gov/pubmed/22417256
234.Arakawa, S., et al. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. J Infect Chemother, 2019. 25: 104.
https://www.ncbi.nlm.nih.gov/pubmed/30420153
235.Armstrong, E.S., et al. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections. BMC Infect Dis, 2016. 16: 710.
https://www.ncbi.nlm.nih.gov/pubmed/27887579
236.Huntington, J.A., et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother, 2016. 71: 2014.
https://www.ncbi.nlm.nih.gov/pubmed/26994090
237.Carmeli, Y., et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis, 2016. 16: 661.
https://www.ncbi.nlm.nih.gov/pubmed/27107460
238.Sims, M., et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother, 2017. 72: 2616.
https://www.ncbi.nlm.nih.gov/pubmed/28575389
239.Wagenlehner, F.M., et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis, 2016. 63: 754.
https://www.ncbi.nlm.nih.gov/pubmed/27313268
240.Kaye, K.S., et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA, 2018. 319: 788.
https://www.ncbi.nlm.nih.gov/pubmed/29486041
241.Wunderink, R.G., et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther, 2018. 7: 439.
https://www.ncbi.nlm.nih.gov/pubmed/30270406
242.Wagenlehner, F.M.E., et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med, 2019. 380: 729.
https://www.ncbi.nlm.nih.gov/pubmed/30786187
243.Portsmouth, S., et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis, 2018. 18: 1319.
https://www.ncbi.nlm.nih.gov/pubmed/30509675
244.Pitout, J.D. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs, 2010. 70: 313.
https://www.ncbi.nlm.nih.gov/pubmed/20166768
245.Mombelli, G., et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med, 1999. 159: 53.
https://www.ncbi.nlm.nih.gov/pubmed/9892331
246.Millar, L.K., et al. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol, 1995. 86: 560.
https://www.ncbi.nlm.nih.gov/pubmed/7675380
247.Wing, D.A., et al. A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy. Obstet Gynecol, 1998. 92: 249.
https://www.ncbi.nlm.nih.gov/pubmed/9699761
248.Ulleryd, P., et al. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis, 2003. 35: 34.
https://www.ncbi.nlm.nih.gov/pubmed/12685882
249.Chihara, S., et al. Staphylococcus aureus bacteriuria as a prognosticator for outcome of Staphylococcus aureus bacteremia: a case-control study. BMC Infect Dis, 2010. 10: 225.
https://www.ncbi.nlm.nih.gov/pubmed/20667139/
250.Papadimitriou-Olivgeris, M., et al. Clinical significance of concomitant bacteriuria in patients with Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis, 2023. 42: 379.
https://pubmed.ncbi.nlm.nih.gov/36725816
251.Kawashima, A., et al. Radiologic evaluation of patients with renal infections. Infect Dis Clin North Am, 2003. 17: 433.
https://pubmed.ncbi.nlm.nih.gov/12848478
252.Zulfiqar, M., et al. Imaging of Renal Infections and Inflammatory Disease. Radiol Clin North Am, 2020. 58: 909.
https://pubmed.ncbi.nlm.nih.gov/32792123
253.Golan, Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis, 2015. 15: 313.
https://pubmed.ncbi.nlm.nih.gov/26243291
254.Singh, K.P., et al. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. Antimicrob Agents Chemother, 2013. 57: 5284.
https://pubmed.ncbi.nlm.nih.gov/23939900
255.Kaye, K.S., et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis, 2019. 69: 2045.
https://pubmed.ncbi.nlm.nih.gov/30861061
256.Wagenlehner, F.M.E., et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med, 2019. 380: 729.
https://www.ncbi.nlm.nih.gov/pubmed/30786187
257.Popejoy, M.W., et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother, 2017. 72: 268.
https://pubmed.ncbi.nlm.nih.gov/27707990
258.Daneman, N., et al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med, 2024.
https://pubmed.ncbi.nlm.nih.gov/40601954
259.McAteer, J., et al. Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia. Clin Infect Dis, 2023. 76: 1604.
https://pubmed.ncbi.nlm.nih.gov/36633559
260.Peterson, J., et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology, 2008. 71: 17.
https://pubmed.ncbi.nlm.nih.gov/18242357
261.Sandberg, T., et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet, 2012. 380: 484.
https://pubmed.ncbi.nlm.nih.gov/22726802
262.van Nieuwkoop, C., et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med, 2017. 15: 70.
https://pubmed.ncbi.nlm.nih.gov/28366170
263.Lafaurie, M., et al. Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Clin Infect Dis, 2023. 76: 2154.
https://pubmed.ncbi.nlm.nih.gov/36785526
264.Erba, L., et al. Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign. Intern Emerg Med, 2021. 16: 313.
https://pubmed.ncbi.nlm.nih.gov/32566969
265.Nicolle, L.E. A practical guide to the management of complicated urinary tract infection. Drugs, 1997. 53: 583.
https://pubmed.ncbi.nlm.nih.gov/9098661
266.Gould, C.V., et al. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol, 2010. 31: 319.
https://www.ncbi.nlm.nih.gov/pubmed/20156062
267.Magill, S.S., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med, 2014. 370: 1198.
https://www.ncbi.nlm.nih.gov/pubmed/24670166
268.Garibaldi, R.A., et al. Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med, 1974. 291: 215.
https://www.ncbi.nlm.nih.gov/pubmed/4834750
269.Kunin, C.M., et al. Prevention of catheter-induced urinary-tract infections by sterile closed drainage. N Engl J Med, 1966. 274: 1155.
https://www.ncbi.nlm.nih.gov/pubmed/5934951
270.Hartstein, A.I., et al. Nosocomial urinary tract infection: a prospective evaluation of 108 catheterized patients. Infect Control, 1981. 2: 380.
https://www.ncbi.nlm.nih.gov/pubmed/6795141
271.Warren, J.W., et al. Fever, bacteremia, and death as complications of bacteriuria in women with long-term urethral catheters. J Infect Dis, 1987. 155: 1151.
https://www.ncbi.nlm.nih.gov/pubmed/3572035
272.Classen, D.C., et al. Prevention of catheter-associated bacteriuria: clinical trial of methods to block three known pathways of infection. Am J Infect Control, 1991. 19: 136.
https://www.ncbi.nlm.nih.gov/pubmed/1863002
273.Saint, S., et al. Preventing catheter-related bacteriuria: should we? Can we? How? Arch Intern Med, 1999. 159: 800.
https://www.ncbi.nlm.nih.gov/pubmed/10219925
274.Maki, D.G., et al. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis, 2001. 7: 342.
https://www.ncbi.nlm.nih.gov/pubmed/11294737
275.Li, F., et al. Risk factors for catheter-associated urinary tract infection among hospitalized patients: A systematic review and meta-analysis of observational studies. J Adv Nurs, 2019. 75: 517.
https://www.ncbi.nlm.nih.gov/pubmed/30259542
276.Jacobsen, S.M., et al. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev, 2008. 21: 26.
https://www.ncbi.nlm.nih.gov/pubmed/18202436
277.Geerlings, S.E., et al. SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections in Adults. SWAB Guidelines, 2013.
https://swab.nl/exec/file/download/84
278.Durant, D.J. Nurse-driven protocols and the prevention of catheter-associated urinary tract infections: A systematic review. Am J Infect Control, 2017. 45: 1331.
https://www.ncbi.nlm.nih.gov/pubmed/28982611
279.Mody, L., et al. A targeted infection prevention intervention in nursing home residents with indwelling devices: a randomized clinical trial. JAMA Intern Med, 2015. 175: 714.
https://www.ncbi.nlm.nih.gov/pubmed/25775048
280.Meddings, J., et al. Systematic Review of Interventions to Reduce Urinary Tract Infection in Nursing Home Residents. J Hosp Med, 2017. 12: 356.
https://www.ncbi.nlm.nih.gov/pubmed/28459908
281.Kachare, S.D., et al. Toward eliminating catheter-associated urinary tract infections in an academic health center. J Surg Res, 2014. 192: 280.
https://www.ncbi.nlm.nih.gov/pubmed/25150082
282.Cao, Y., et al. Comparison of the preventive effect of urethral cleaning versus disinfection for catheter-associated urinary tract infections in adults: A network meta-analysis. Int J Infect Dis, 2018. 76: 102.
https://www.ncbi.nlm.nih.gov/pubmed/30243912
283.Noto, M.J., et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA, 2015. 313: 369.
https://www.ncbi.nlm.nih.gov/pubmed/25602496
284.Huang, H.P., et al. The efficacy of daily chlorhexidine bathing for preventing healthcare-associated infections in adult intensive care units. Korean J Intern Med, 2016. 31: 1159.
https://www.ncbi.nlm.nih.gov/pubmed/27048258
285.Li, M., et al. The effect of bladder catheterization on the incidence of urinary tract infection in laboring women with epidural analgesia: a meta-analysis of randomized controlled trials. Int Urogynecol J, 2019. 30: 1419.
https://www.ncbi.nlm.nih.gov/pubmed/30834958
286.Gibson, K.E., et al. Indwelling urethral versus suprapubic catheters in nursing home residents: determining the safest option for long-term use. J Hosp Infect, 2019. 102: 219.
https://www.ncbi.nlm.nih.gov/pubmed/30056015
287.Kidd, E.A., et al. Urethral (indwelling or intermittent) or suprapubic routes for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev, 2015. 2015: CD004203.
https://www.ncbi.nlm.nih.gov/pubmed/26661940
288.Jamison, J., et al. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev, 2013. 18: CD004375.
https://www.ncbi.nlm.nih.gov/pubmed/24249436
289.Kranz, J., et al. Catheter-Associated Urinary Tract Infections in Adult Patients. Dtsch Arztebl Int, 2020. 117: 83.
https://www.ncbi.nlm.nih.gov/pubmed/32102727
290.Rognoni, C., et al. Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urol, 2017. 17: 4.
https://www.ncbi.nlm.nih.gov/pubmed/28073354
291.Tradewell, M., et al. Systematic review and practice policy statements on urinary tract infection prevention in adults with spina bifida. Transl Androl Urol, 2018. 7: S205.
https://www.ncbi.nlm.nih.gov/pubmed/29928619
292.Akcam, F.Z., et al. An investigation of the effectiveness against bacteriuria of silver-coated catheters in short-term urinary catheter applications: A randomized controlled study. J Infect Chemother, 2019. 25: 797.
https://www.ncbi.nlm.nih.gov/pubmed/31030965
293.Singh, R., et al. Randomized controlled trial of silver-alloy-impregnated suprapubic catheters versus standard suprapubic catheters in assessing urinary tract infection rates in urogynecology patients. Int Urogynecol J, 2019. 30: 779.
https://www.ncbi.nlm.nih.gov/pubmed/30145671
294.Lam, T.B., et al. Types of indwelling urethral catheters for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev, 2014. 2014: CD004013.
https://www.ncbi.nlm.nih.gov/pubmed/25248140
295.Menezes, F.G., et al. A randomized clinical trial comparing Nitrofurazone-coated and uncoated urinary catheters in kidney transplant recipients: Results from a pilot study. Transpl Infect Dis, 2019. 21: e13031.
https://www.ncbi.nlm.nih.gov/pubmed/30451342
296.Bonfill, X., et al. Efficacy and safety of urinary catheters with silver alloy coating in patients with spinal cord injury: a multicentric pragmatic randomized controlled trial. The ESCALE trial. Spine J, 2017. 17: 1650.
https://www.ncbi.nlm.nih.gov/pubmed/28578163
297.Lusardi, G., et al. Antibiotic prophylaxis for short-term catheter bladder drainage in adults. Cochrane Database Syst Rev, 2013. 2013: CD005428.
https://www.ncbi.nlm.nih.gov/pubmed/23824735
298.Pickard, R., et al. Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: the AnTIC RCT. Health Technol Assess, 2018. 22: 1.
https://www.ncbi.nlm.nih.gov/pubmed/29766842
299.Cek, M., et al. Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003-2010. World J Urol, 2014. 32: 1587.
https://www.ncbi.nlm.nih.gov/pubmed/24452449
300.Darouiche, R.O., et al. Short versus long course of antibiotics for catheter-associated urinary tract infections in patients with spinal cord injury: a randomized controlled noninferiority trial. Arch Phys Med Rehabil, 2014. 95: 290.
https://www.ncbi.nlm.nih.gov/pubmed/24035770
301.Saint, S., et al. Preventing Catheter-Associated Urinary Tract Infections. N Engl J Med, 2016. 375: 1298.
https://www.ncbi.nlm.nih.gov/pubmed/27682041
302.Society of Critical Care Medicine. Surviving Sepsis Campaign Guidelines 2021.
https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-guidelines-2021#Recommendations
303.Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, S3-Leitlinie Urethritis: Management der Urethritis bei männlichen* Jugendlichen und Erwachsenen. 2024.
https://register.awmf.org/de/leitlinien/detail/013-099
304.Zhang, N., et al. Are Ureaplasma spp. a cause of nongonococcal urethritis? A systematic review and meta-analysis. PLoS One, 2014. 9: e113771.
https://www.ncbi.nlm.nih.gov/pubmed/25463970
305.Horner, P.J., et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS, 2016. 27: 928.
https://www.ncbi.nlm.nih.gov/pubmed/27147267
306.Workowski, K.A., et al. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep, 2015. 64: 1.
https://www.ncbi.nlm.nih.gov/pubmed/26042815
307.Rietmeijer, C.A., et al. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis, 2012. 39: 18.
https://www.ncbi.nlm.nih.gov/pubmed/22183839
308.Couldwell, D.L., et al. Ureaplasma urealyticum is significantly associated with non-gonococcal urethritis in heterosexual Sydney men. Int J STD AIDS, 2010. 21: 337.
https://www.ncbi.nlm.nih.gov/pubmed/20498103
309.Berntsson, M., et al. Viral and bacterial aetiologies of male urethritis: findings of a high prevalence of Epstein-Barr virus. Int J STD AIDS, 2010. 21: 191.
https://www.ncbi.nlm.nih.gov/pubmed/20215624
310.Sarier, M., et al. Microscopy of Gram-stained urethral smear in the diagnosis of urethritis: Which threshold value should be selected? Andrologia, 2018. 50: e13143.
https://www.ncbi.nlm.nih.gov/pubmed/30238498
311.Moi, H., et al. Microscopy of Stained Urethral Smear in Male Urethritis; Which Cutoff Should be Used? Sex Transm Dis, 2017. 44: 189.
https://www.ncbi.nlm.nih.gov/pubmed/28178118
312.Mensforth, S., et al. Auditing the use and assessing the clinical utility of microscopy as a point-of-care test for Neisseria gonorrhoeae in a Sexual Health clinic. Int J STD AIDS, 2018. 29: 157.
https://www.ncbi.nlm.nih.gov/pubmed/28705094
313.Atkinson, L.M., et al. ‘The waiting game’: are current chlamydia and gonorrhoea near-patient/point-of-care tests acceptable to service users and will they impact on treatment? Int J STD AIDS, 2016. 27: 650.
https://www.ncbi.nlm.nih.gov/pubmed/26092579
314.Harding-Esch, E.M., et al. Impact of deploying multiple point-of-care tests with a ‘sample first’ approach on a sexual health clinical care pathway. A service evaluation. Sex Transm Infect, 2017. 93: 424.
https://www.ncbi.nlm.nih.gov/pubmed/28159916
315.Jensen, J.S., et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol, 2016. 30: 1650.
https://www.ncbi.nlm.nih.gov/pubmed/27505296
316.Centers for Disease, C., et al. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep, 2014. 63: 1.
https://www.ncbi.nlm.nih.gov/pubmed/24622331
317.Miller, J.M., et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis, 2018. 67: e1.
https://www.ncbi.nlm.nih.gov/pubmed/29955859
318.Sena, A.C., et al. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther, 2014. 12: 673.
https://www.ncbi.nlm.nih.gov/pubmed/24555561
319.Falk, L., et al. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women. J Antimicrob Chemother, 2015. 70: 3134.
https://www.ncbi.nlm.nih.gov/pubmed/26283670
320.Ong, J.J., et al. Should Female Partners of Men With Non-Gonococcal Urethritis, Negative for Chlamydia trachomatis and Mycoplasma genitalium, Be Informed and Treated? Clinical Outcomes From a Partner Study of Heterosexual Men With NGU. Sex Transm Dis, 2017. 44: 126.
https://www.ncbi.nlm.nih.gov/pubmed/28079749
321.Kirkcaldy, R.D., et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis, 2014. 59: 1083.
https://www.ncbi.nlm.nih.gov/pubmed/25031289
322.Hathorn, E., et al. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Syst Rev, 2014. 3: 104.
https://www.ncbi.nlm.nih.gov/pubmed/25239090
323.Soda, M., et al. Evaluation of the Microbiological Efficacy of a Single 2-Gram Dose of Extended-Release Azithromycin by Population Pharmacokinetics and Simulation in Japanese Patients with Gonococcal Urethritis. Antimicrob Agents Chemother, 2018. 62: e01409.
https://www.ncbi.nlm.nih.gov/pubmed/29038284
324.Takahashi, S., et al. Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis. Antibiotics (Basel), 2014. 3: 109.
https://www.ncbi.nlm.nih.gov/pubmed/27025738
325.Yasuda, M., et al. A single 2 g oral dose of extended-release azithromycin for treatment of gonococcal urethritis. J Antimicrob Chemother, 2014. 69: 3116.
https://www.ncbi.nlm.nih.gov/pubmed/24948703
326.Kojima, M., et al. Single-dose treatment of male patients with gonococcal urethritis using 2g spectinomycin: microbiological and clinical evaluations. Int J Antimicrob Agents, 2008. 32: 50.
https://www.ncbi.nlm.nih.gov/pubmed/18539003
327.Moran, J.S., et al. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis, 1995. 20 Suppl 1: S47.
https://www.ncbi.nlm.nih.gov/pubmed/7795109
328.Yuan, Z., et al. Randomized controlled clinical trial on the efficacy of fosfomycin trometamol for uncomplicated gonococcal urethritis in men. Clin Microbiol Infect, 2016. 22: 507.
https://www.ncbi.nlm.nih.gov/pubmed/27064136
329.Lanjouw, E., et al. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS, 2016. 27: 333.
https://www.ncbi.nlm.nih.gov/pubmed/26608577
330.Manhart, L.E., et al. Efficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections. Clin Infect Dis, 2015. 61 Suppl 8: S802.
https://www.ncbi.nlm.nih.gov/pubmed/26602619
331.Khosropour, C.M., et al. Efficacy of standard therapies against Ureaplasma species and persistence among men with non-gonococcal urethritis enrolled in a randomised controlled trial. Sex Transm Infect, 2015. 91: 308.
https://www.ncbi.nlm.nih.gov/pubmed/25616607
332.Wagenlehner, F.M., et al. The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Dtsch Arztebl Int, 2016. 113: 11.
https://www.ncbi.nlm.nih.gov/pubmed/26931526
333.Muratani, T., et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol, 2008. 15: 837.
https://www.ncbi.nlm.nih.gov/pubmed/18665871
334.Alexander, R.B., et al. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology, 1998. 52: 744.
https://www.ncbi.nlm.nih.gov/pubmed/9801092
335.Alexander, R.B., et al. Chronic prostatitis: results of an Internet survey. Urology, 1996. 48: 568.
https://www.ncbi.nlm.nih.gov/pubmed/8886062
336.Zermann, D.H., et al. Neurourological insights into the etiology of genitourinary pain in men. J Urol, 1999. 161: 903.
https://www.ncbi.nlm.nih.gov/pubmed/10022711
337.Perletti, G., et al. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev, 2013: CD009071.
https://www.ncbi.nlm.nih.gov/pubmed/23934982
338.Dadashpour. M, et al. Acute Prostatitis After Transrectal Ultrasound-guided Prostate Biopsy: Comparing Two Different Antibiotic Prophylaxis Regimen. Biomed Pharmacol J, 2016. 9: 593.
https://biomedpharmajournal.org/vol9no2/acute-prostatitis-after-transrectal-ultrasound-guided-prostate-biopsy-comparing-two-different-antibiotic-prophylaxis-regimen/
339.Schaeffer, A.J., et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol, 2005. 174: 161.
https://www.ncbi.nlm.nih.gov/pubmed/15947609
340.Skerk, V., et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents, 2003. 21: 457.
https://www.ncbi.nlm.nih.gov/pubmed/12727080
341.Vickovic, N., et al. Metronidazole 1.5 gram dose for 7 or 14 days in the treatment of patients with chronic prostatitis caused by Trichomonas vaginalis: A randomized study. J Chemother, 2010. 22: 364.
https://www.ncbi.nlm.nih.gov/pubmed/21123162
342.Cai, T., et al. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents, 2009. 33: 549.
https://www.ncbi.nlm.nih.gov/pubmed/19181486
343.Aliaev Iu, G., et al. [Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. Urologiia, 2008: 52.
https://www.ncbi.nlm.nih.gov/pubmed/19256057
344.Lipsky, B.A., et al. Treatment of bacterial prostatitis. Clin Infect Dis, 2010. 50: 1641.
https://www.ncbi.nlm.nih.gov/pubmed/20459324
345.Wise, G.J., et al. Atypical infections of the prostate. Current Prostate Reports, 2008. 6: 86.
https://link.springer.com/article/10.1007/s11918-008-0014-2
346.Turner, J.A., et al. Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. J Urol, 2003. 169: 580.
https://www.ncbi.nlm.nih.gov/pubmed/12544311
347.Zegarra Montes, L.Z., et al. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int Braz J Urol, 2008. 34: 30.
https://www.ncbi.nlm.nih.gov/pubmed/18341719
348.Budia, A., et al. Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method. Scand J Urol Nephrol, 2006. 40: 326.
https://www.ncbi.nlm.nih.gov/pubmed/16916775
349.Skerk, V., et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents, 2004. 24 Suppl 1: S53.
https://www.ncbi.nlm.nih.gov/pubmed/15364308
350.Schneider, H., et al. The 2001 Giessen Cohort Study on patients with prostatitis syndrome--an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia, 2003. 35: 258.
https://www.ncbi.nlm.nih.gov/pubmed/14535851
351.Naber, K.G., et al., Prostatitits, epididymitis and orchitis, in Infectious diseases, D. Armstrong & J. Cohen, Editors. 1999, Mosby: London.
352.Badalyan, R.R., et al. Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Andrologia, 2003. 35: 263.
https://www.ncbi.nlm.nih.gov/pubmed/14535852
353.Berger, R.E., Epididymitis., in Sexually transmitted diseases, K.K. Holmes, P.-A. Mardh, P.F. Sparling & P.J. Wiesner, Editors. 1984, McGraw-Hill: New York.
354.Robinson, A.J., et al. Acute epididymitis: why patient and consort must be investigated. Br J Urol, 1990. 66: 642.
https://www.ncbi.nlm.nih.gov/pubmed/2265337
355.Schaeffer, A.J. Prostatitis: US perspective. Int J Antimicrob Agents, 1999. 11: 205.
https://www.ncbi.nlm.nih.gov/pubmed/10394972
356.Krieger, J.N., et al. NIH consensus definition and classification of prostatitis. JAMA, 1999. 282: 236.
https://www.ncbi.nlm.nih.gov/pubmed/10422990
357.Workshop Committee of the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), Chronic prostatitis workshop. 1995: Bethesda, Maryland.
358.Krieger, J.N., et al. Chronic pelvic pains represent the most prominent urogenital symptoms of “chronic prostatitis”. Urology, 1996. 48: 715.
https://www.ncbi.nlm.nih.gov/pubmed/8911515
359.Nickel, J.C. Effective office management of chronic prostatitis. Urol Clin North Am, 1998. 25: 677.
https://www.ncbi.nlm.nih.gov/pubmed/10026774
360.Etienne, M., et al. Performance of the urine leukocyte esterase and nitrite dipstick test for the diagnosis of acute prostatitis. Clin Infect Dis, 2008. 46: 951.
https://www.ncbi.nlm.nih.gov/pubmed/18288905
361.Meares, E.M., et al. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol, 1968. 5: 492.
https://www.ncbi.nlm.nih.gov/pubmed/4870505
362.Nickel, J.C., et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol, 2006. 176: 119.
https://www.ncbi.nlm.nih.gov/pubmed/16753385
363.Doble, A., et al. Ultrasonographic findings in prostatitis. Urol Clin North Am, 1989. 16: 763.
https://www.ncbi.nlm.nih.gov/pubmed/2683305
364.Papp, J.R., et al. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014. MMWR Recomm Rep, 2014. 63: 1.
https://pubmed.ncbi.nlm.nih.gov/24622331
365.Polascik, T.J., et al. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol, 1999. 162: 293.
https://www.ncbi.nlm.nih.gov/pubmed/10411025
366.Wagenlehner, F.M., et al. Bacterial prostatitis. World J Urol, 2013. 31: 711.
https://www.ncbi.nlm.nih.gov/pubmed/23519458
367.Gill, B.C., et al. Bacterial prostatitis. Curr Opin Infect Dis, 2016. 29: 86.
https://www.ncbi.nlm.nih.gov/pubmed/26555038
368.Wagenlehner, F.M., et al. Prostatitis: the role of antibiotic treatment. World J Urol, 2003. 21: 105.
https://www.ncbi.nlm.nih.gov/pubmed/12687400
369.Krieger, J.N. Recurrent lower urinary tract infections in men. J New Rem Clin, 1998. 47: 4.
https://www.sciencedirect.com/science/article/abs/pii/S0022534717362924
370.Litwin, M.S., et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol, 1999. 162: 369.
https://www.ncbi.nlm.nih.gov/pubmed/10411041
371.Schaeffer, A.J., et al. Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2003. 43: 1.
https://www.sciencedirect.com/science/article/abs/pii/S1569905602001914
372.Bjerklund Johansen, T.E., et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol, 1998. 34: 457.
https://www.ncbi.nlm.nih.gov/pubmed/9831786
373.Cai, T., et al. Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study. Methods Find Exp Clin Pharmacol, 2010. 32: 39.
https://www.ncbi.nlm.nih.gov/pubmed/20383345
374.Smelov, V., et al. Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome. Andrologia, 2005. 37: 61.
https://www.ncbi.nlm.nih.gov/pubmed/16026425
375.Ohkawa, M., et al. Antimicrobial treatment for chronic prostatitis as a means of defining the role of Ureaplasma urealyticum. Urol Int, 1993. 51: 129.
https://www.ncbi.nlm.nih.gov/pubmed/8249222
376.Jimenez-Cruz, J.F., et al. Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol, 1988. 139: 967.
https://www.ncbi.nlm.nih.gov/pubmed/3283385
377.Mayersak, J.S. Transrectal ultrasonography directed intraprostatic injection of gentamycin-xylocaine in the management of the benign painful prostate syndrome. A report of a 5 year clinical study of 75 patients. Int Surg, 1998. 83: 347.
https://www.ncbi.nlm.nih.gov/pubmed/10096759
378.Hua, L.X., et al. [The diagnosis and treatment of acute prostatitis: report of 35 cases]. Zhonghua Nan Ke Xue, 2005. 11: 897.
https://www.ncbi.nlm.nih.gov/pubmed/16398358
379.Yoon, B.I., et al. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother, 2012. 18: 444.
https://www.ncbi.nlm.nih.gov/pubmed/22215226
380.Ludwig, M., et al. Diagnosis and therapeutic management of 18 patients with prostatic abscess. Urology, 1999. 53: 340.
https://www.ncbi.nlm.nih.gov/pubmed/9933051
381.Chou, Y.H., et al. Prostatic abscess: transrectal color Doppler ultrasonic diagnosis and minimally invasive therapeutic management. Ultrasound Med Biol, 2004. 30: 719.
https://www.ncbi.nlm.nih.gov/pubmed/15219951
382.Çek, M., et al. Acute and Chronic Epididymitis in EAU-EBU Update Series. Eur Urol Suppl 2017. 16: 124.
https://www.sciencedirect.com/science/article/abs/pii/S1569905617300568
383.Pilatz, A., et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol, 2015. 68: 428.
https://www.ncbi.nlm.nih.gov/pubmed/25542628
384.Harnisch, J.P., et al. Aetiology of acute epididymitis. Lancet, 1977. 1: 819.
https://www.ncbi.nlm.nih.gov/pubmed/67333
385.Shigemura, K., et al. Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study. World J Urol, 2020. 38: 733.
https://www.ncbi.nlm.nih.gov/pubmed/30949801
386.Street, E., et al. The 2016 European guideline on the management of epididymo-orchitis. IUSTI, 2016.
https://www.ncbi.nlm.nih.gov/pubmed/28632112
387.Chirwa, M., et al. United Kingdom British association for sexual health and HIV national guideline for the management of epididymo-orchitis, 2020. Int J STD AIDS, 2021. 32: 884.
https://www.ncbi.nlm.nih.gov/pubmed/34009058
388.Abbara, A., et al. Etiology and management of genitourinary tuberculosis. Nat Rev Urol, 2011. 8: 678.
https://www.ncbi.nlm.nih.gov/pubmed/22157940
389.Zitek, T., et al. Assessing the Utility of Ultrasound and Urinalysis for Patients with Possible Epididymo-Orchitis - A Retrospective Study. Open Access Emerg Med, 2020. 12: 47.
https://www.ncbi.nlm.nih.gov/pubmed/32214857
390.Capet, J., et al. Is follow-up ultrasound necessary after acute epididymitis? A retrospective analysis from a large university hospital. Scand J Urol, 2018. 52: 445.
https://www.ncbi.nlm.nih.gov/pubmed/30600755
391.Sadahira, T., et al. Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. J Infect Chemother, 2017. 23: 214.
https://www.ncbi.nlm.nih.gov/pubmed/28089362
392.Street, E., et al. BASHH 2010 United Kingdom national guideline for the management of epididymo-orchitis. 2010.
http://www.bashh.org/documents/3546.pdf
393.Fifer, H., et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS, 2020. 31: 4.
https://www.ncbi.nlm.nih.gov/pubmed/31870237
394.Eickhoff, J.H., et al. A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididymitis in men over 40 years of age. BJU Int, 1999. 84: 827.
https://www.ncbi.nlm.nih.gov/pubmed/10532980
395.Banyra, O., et al. Acute epididymo-orchitis: relevance of local classification and partner’s follow-up. Cent European J Urol, 2019. 72: 324.
https://www.ncbi.nlm.nih.gov/pubmed/31720038
396.Pilatz, A., et al. Impact of Bacterial Epididymitis on Semen Quality after Antibiotic Treatment. J Urol, 2012. 187: e443.
https://www.auajournals.org/doi/10.1016/j.juro.2012.02.1199
397.Haddadeen, C., et al. Comparative regional audit of urology and genito-urinary departments in the management of acute epididymo-orchitis. HIV Medicine, 2010. 11: 45.
https://www.researchgate.net/publication/295130036
398.Nicholson, A., et al. Management of epididymo-orchitis in primary care: results from a large UK primary care database. Br J Gen Pract, 2010. 60: e407.
https://www.ncbi.nlm.nih.gov/pubmed/20883615
399.Andersen, B., et al. Impact of intensified testing for urogenital Chlamydia trachomatis infections: a randomised study with 9-year follow-up. Sex Transm Infect, 2011. 87: 156.
https://www.ncbi.nlm.nih.gov/pubmed/21097811
400.Chennamsetty, A., et al. Contemporary diagnosis and management of Fournier’s gangrene. Ther Adv Urol, 2015. 7: 203.
https://www.ncbi.nlm.nih.gov/pubmed/26445600
401.Eke, N. Fournier’s gangrene: a review of 1726 cases. Br J Surg, 2000. 87: 718.
https://www.ncbi.nlm.nih.gov/pubmed/10848848
402.Subrahmanyam, U., et al. Honey dressing beneficial in treatment of fournier’s gangrene. Indian J Surg, 2004. 66: 75.
https://www.researchgate.net/publication/289257622
403.Jallali, N., et al. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg, 2005. 189: 462.
https://pubmed.ncbi.nlm.nih.gov/15820462
404.Karian, L.S., et al. Reconstruction of Defects After Fournier Gangrene: A Systematic Review. Eplasty, 2015. 15: e18.
https://www.ncbi.nlm.nih.gov/pubmed/26171090
405.Furr, J., et al. Contemporary Trends in the Inpatient Management of Fournier’s Gangrene: Predictors of Length of Stay and Mortality Based on Population-based Sample. Urology, 2017. 102: 79.
https://www.ncbi.nlm.nih.gov/pubmed/27693572
406.Kim, S.Y., et al. A contemporary analysis of Fournier gangrene using the National Surgical Quality Improvement Program. Urology, 2015. 85: 1052.
https://www.ncbi.nlm.nih.gov/pubmed/25770725
407.Sorensen, M.D., et al. Fournier’s Gangrene: Epidemiology and Outcomes in the General US Population. Urol Int, 2016. 97: 249.
https://www.ncbi.nlm.nih.gov/pubmed/27172977
408.Roghmann, F., et al. Is there a need for the Fournier’s gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier’s gangrene. BJU International, 2012. 110: 1359.
https://pubmed.ncbi.nlm.nih.gov/22494217
409.Lauerman, M.H., et al. Less is more? Antibiotic duration and outcomes in Fournier’s gangrene. J Trauma Acute Care Surg, 2017. 83: 443.
https://www.ncbi.nlm.nih.gov/pubmed/28538648
410.Li, C., et al. Hyperbaric oxygen therapy as an adjuvant therapy for comprehensive treatment of Fournier’s gangrene. Urologia Internationalis, 2015. 94: 453.
https://pubmed.ncbi.nlm.nih.gov/25677386/
411.Stevens, D.L., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis, 2014. 59: 147.
https://www.ncbi.nlm.nih.gov/pubmed/24947530
412.Lyu, Z., et al. Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis. BMC Infect Dis, 2017. 17: 714.
https://www.ncbi.nlm.nih.gov/pubmed/29121862
413.Rodriguez-Alvarez, M.I., et al. Prevalence and Risk Factors of Human Papillomavirus in Male Patients: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health, 2018. 15: 2210.
https://www.ncbi.nlm.nih.gov/pubmed/30309014
414.Vaccarella, S., et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis, 2011. 204: 1500.
https://www.ncbi.nlm.nih.gov/pubmed/21908729
415.Nakashima, K., et al. Risk factors for human papillomavirus detection in urine samples of heterosexual men visiting urological clinics in Japan. J Infect Chemother, 2018. 24: 713.
https://www.ncbi.nlm.nih.gov/pubmed/29759898
416.Luttmer, R., et al. Presence of human papillomavirus in semen in relation to semen quality. Hum Reprod, 2016. 31: 280.
https://www.ncbi.nlm.nih.gov/pubmed/26724799
417.Souho, T., et al. Human papillomavirus infection and fertility alteration: a systematic review. PLoS One, 2015. 10: e0126936.
https://www.ncbi.nlm.nih.gov/pubmed/25992782
418.Azevedo, J., et al. Epidemiology of human papillomavirus on anogenital warts in Portugal - The HERCOLES study. J Eur Acad Dermatol Venereol, 2017. 31: 1342.
https://www.ncbi.nlm.nih.gov/pubmed/28485812
419.Wei, F., et al. Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study. Clin Infect Dis, 2020. 70: 82.
https://www.ncbi.nlm.nih.gov/pubmed/30852604
420.Harder, T., et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med, 2018. 16: 110.
https://www.ncbi.nlm.nih.gov/pubmed/30016957
421.Shigeishi, H., et al. Risk Factors for Oral Human Papillomavirus Infection in Healthy Individuals: A Systematic Review and Meta-Analysis. J Clin Med Res, 2016. 8: 721.
https://www.ncbi.nlm.nih.gov/pubmed/27635177
422.Tam, S., et al. The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis. Oral Oncol, 2018. 82: 91.
https://www.ncbi.nlm.nih.gov/pubmed/29909908
423.Dalla Torre, D., et al. The impact of sexual behavior on oral HPV infections in young unvaccinated adults. Clin Oral Investig, 2016. 20: 1551.
https://www.ncbi.nlm.nih.gov/pubmed/26526324
424.Geskus, R.B., et al. Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors. AIDS (london, england), 2016. 30: 37.
https://pubmed.ncbi.nlm.nih.gov/26355673
425.Hebnes, J.B., et al. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med, 2014. 11: 2630.
https://www.ncbi.nlm.nih.gov/pubmed/25088239
426.Kaderli, R., et al. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis, 2014. 29: 899.
https://www.ncbi.nlm.nih.gov/pubmed/24935346
427.Liu, M., et al. Transmission of genital human papillomavirus infection in couples: a population-based cohort study in rural China. Sci Rep, 2015. 5: 10986.
https://www.ncbi.nlm.nih.gov/pubmed/26204471
428.Taylor, S., et al. The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature. BMC Infect Dis, 2016. 16: 293.
https://www.ncbi.nlm.nih.gov/pubmed/27301867
429.Albero, G., et al. Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infect Dis, 2013. 13: 18.
https://www.ncbi.nlm.nih.gov/pubmed/23327450
430.Lam, J.U., et al. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen, 2014. 21: 38.
https://www.ncbi.nlm.nih.gov/pubmed/24488594
431.Larke, N., et al. Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis. J Infect Dis, 2011. 204: 1375.
https://www.ncbi.nlm.nih.gov/pubmed/21965090
432.Liu, Z., et al. Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. Sex Health, 2016. 13: 10.
https://www.ncbi.nlm.nih.gov/pubmed/26433493
433.Albero, G., et al. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis, 2012. 39: 104.
https://www.ncbi.nlm.nih.gov/pubmed/22249298
434.Zaak, D., et al. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology, 2003. 61: 1011.
https://www.ncbi.nlm.nih.gov/pubmed/12736026
435.Vives, A., et al. Urethral condylomas in men: experience in 123 patients without previous treatment. Int J STD AIDS, 2016. 27: 39.
https://www.ncbi.nlm.nih.gov/pubmed/25712107
436.Gilson, R., et al. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol, 2020. 34: 1644.
https://www.ncbi.nlm.nih.gov/pubmed/32735077
437.Edwards, L., et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol, 1998. 134: 25.
https://www.ncbi.nlm.nih.gov/pubmed/9449906
438.Saiag, P., et al. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br J Dermatol, 2009. 161: 904.
https://www.ncbi.nlm.nih.gov/pubmed/19466962
439.Grillo-Ardila, C.F., et al. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev, 2014: CD010389.
https://www.ncbi.nlm.nih.gov/pubmed/25362229
440.Tatti, S., et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol, 2008. 111: 1371.
https://www.ncbi.nlm.nih.gov/pubmed/18515521
441.Puviani, M., et al. Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO(2) ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial. Int J STD AIDS, 2019. 30: 131.
https://www.ncbi.nlm.nih.gov/pubmed/30236042
442.Werner, R.N., et al. Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect, 2017. 93: 155.
https://www.ncbi.nlm.nih.gov/pubmed/27803240
443.Camargo, C.L., et al. A prospective, open, comparative study of 5% potassium hydroxide solution versus cryotherapy in the treatment of genital warts in men. An Bras Dermatol, 2014. 89: 236.
https://www.ncbi.nlm.nih.gov/pubmed/24770498
444.Kodner, C.M., et al. Management of genital warts. Am Fam Physician, 2004. 70: 2335.
https://www.ncbi.nlm.nih.gov/pubmed/15617297
445.Scheinfeld, N., et al. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J, 2006. 12: 5.
https://www.ncbi.nlm.nih.gov/pubmed/16638419
446.Barton, S., et al. Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis. BMJ Open, 2019. 9: e027765.
https://www.ncbi.nlm.nih.gov/pubmed/31676644
447.Tobian, A.A., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med, 2009. 360: 1298.
https://www.ncbi.nlm.nih.gov/pubmed/19321868
448.Schmeler, K.M., et al. Expanding the benefits of HPV vaccination to boys and men. Lancet, 2016. 387: 1798.
https://www.ncbi.nlm.nih.gov/pubmed/27203488
449.Rosales, R., et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther, 2014. 25: 1035.
https://www.ncbi.nlm.nih.gov/pubmed/25275724
450.Mikamo, H., et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. Vaccine, 2019. 37: 1651.
https://www.ncbi.nlm.nih.gov/pubmed/30797638
451.Bergman, H., et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev, 2019. 2019: CD013479.
https://www.ncbi.nlm.nih.gov/pubmed/31755549
452.Dibble, K.E., et al. A Systematic Literature Review of HPV Vaccination Barriers Among Adolescent and Young Adult Males. J Adolesc Young Adult Oncol, 2019. 8: 495.
https://www.ncbi.nlm.nih.gov/pubmed/31090474
453.Richman, A.R., et al. A randomized intervention study to evaluate whether electronic messaging can increase HPV vaccine uptake and knowledge. J Am Coll Health, 2016. 20: S28.
https://pubmed.ncbi.nlm.nih.gov/26821923
454.Dabestani, N., et al. Time Trends in First-Episode Genital Herpes Simplex Virus Infections in an Urban Sexually Transmitted Disease Clinic. Sex Transm Dis, 2019. 46: 795.
https://pubmed.ncbi.nlm.nih.gov/31764767
455.Yousuf, W., et al. Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. BMJ Glob Health, 2020. 5.
https://www.ncbi.nlm.nih.gov/pubmed/32675066
456.Aimukdad, S., et al. Epidemiology of herpes simplex virus type 1 and genital herpes in Australia and New Zealand: systematic review, meta-analyses and meta-regressions. Epidemiol Infect, 2023. 151: e33.
https://www.ncbi.nlm.nih.gov/pubmed/36750224
457.Alareeki, A., et al. Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions. Lancet Reg Health Eur, 2023. 25: 100558.
https://www.ncbi.nlm.nih.gov/pubmed/36818238
458.Aimukdad, S., et al. Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression. Lancet Reg Health West Pac, 2021. 12: 100176.
https://www.ncbi.nlm.nih.gov/pubmed/34527970
459.Aimukdad, S., et al. Epidemiology of Herpes Simplex Virus Type 2 in Canada, Australia, and New Zealand: Systematic Review, Meta-Analyses, and Meta-Regressions. Sex Transm Dis, 2022. 49: 403.
https://www.ncbi.nlm.nih.gov/pubmed/35608096
460.Magaret, A.S., et al. Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis, 2016. 62: 456.
https://www.ncbi.nlm.nih.gov/pubmed/26578538
461.Hochberg, C.H., et al. Population and dyadic-based seroincidence of herpes simplex virus-2 and syphilis in southern India. Sex Transm Infect, 2015. 91: 375.
https://www.ncbi.nlm.nih.gov/pubmed/25605970
462.Sasso, B.M., et al. Herpes simplex virus mucocutaneous tumoural lesions - Systematic review. J Clin Virol, 2020. 123: 104246.
https://www.ncbi.nlm.nih.gov/pubmed/31927151
463.Johnston, C., et al. Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 U(L) and U(S) regions from genital swabs collected from 3 continents. Virology, 2017. 510: 90.
https://www.ncbi.nlm.nih.gov/pubmed/28711653
464.Liu, J., et al. Development and evaluation of the quantitative real-time PCR assay in detection and typing of herpes simplex virus in swab specimens from patients with genital herpes. Int J Clin Exp Med, 2015. 8: 18758.
https://www.ncbi.nlm.nih.gov/pubmed/26770492
465.Young, S., et al. Multicenter evaluation of the Luminex® ARIES® HSV 1&2 Assay for the detection of herpes simplex virus types 1 and 2 in cutaneous and mucocutaneous lesion specimens. Expert Rev Mol Diagn, 2016. 16: 1241.
https://www.ncbi.nlm.nih.gov/pubmed/27771977
466.Schremser, V., et al. Polymerase chain reaction for the diagnosis of herpesvirus infections in dermatology : Analysis of clinical data. Wien Klin Wochenschr, 2020. 132: 35.
https://www.ncbi.nlm.nih.gov/pubmed/31820101
467.Binnicker, M.J., et al. Automated processing, extraction and detection of herpes simplex virus types 1 and 2: A comparative evaluation of three commercial platforms using clinical specimens. J Clin Virol, 2017. 89: 30.
https://www.ncbi.nlm.nih.gov/pubmed/28226272
468.Patwardhan, V., et al. A Comparative Analysis of Polymerase Chain Reaction and Direct Fluorescent Antibody Test for Diagnosis of Genital Herpes. J Lab Physicians, 2017. 9: 53.
https://www.ncbi.nlm.nih.gov/pubmed/28042218
469.Patel, E.U., et al. Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessment. BMC Infect Dis, 2015. 15: 398.
https://www.ncbi.nlm.nih.gov/pubmed/26423888
470.Patwardhan, V., et al. Role of type-specific herpes simplex virus-1 and 2 serology as a diagnostic modality in patients with clinically suspected genital herpes: A comparative study in Indian population from a tertiary care hospital. Indian J Pathol Microbiol, 2016. 59: 318.
https://www.ncbi.nlm.nih.gov/pubmed/27510668
471.Liu, T., et al. Production of a fragment of glycoprotein G of herpes simplex virus type 2 and evaluation of its diagnostic potential. Singapore Med J, 2015. 56: 346.
https://www.ncbi.nlm.nih.gov/pubmed/25532518
472.Al-Shobaili, H., et al. Evaluation of the HerpeSelect Express rapid test in the detection of herpes simplex virus type 2 antibodies in patients with genital ulcer disease. J Clin Lab Anal, 2015. 29: 43.
https://www.ncbi.nlm.nih.gov/pubmed/24687953
473.Shevlin, E., et al. Comparative performance of the Uni-Gold™ HSV-2 Rapid: a point-of-care HSV-2 diagnostic test in unselected sera from a reference laboratory. J Clin Virol, 2014. 61: 378.
https://www.ncbi.nlm.nih.gov/pubmed/25200648
474.Wald, A., et al. Helicase-Primase Inhibitor Pritelivir for HSV-2 Infection. N Engl J Med, 2014. 370: 201.
https://pubmed.ncbi.nlm.nih.gov/24428466
475.Takada, A., et al. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes. Clin Pharmacol Drug Dev, 2014. 3: 365.
https://www.ncbi.nlm.nih.gov/pubmed/27129009
476.Kawashima, M., et al. Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Open Forum Infect Dis, 2022. 9: ofac494.
https://www.ncbi.nlm.nih.gov/pubmed/36267254
477.You, Y., et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol, 2015. 42: 596.
https://www.ncbi.nlm.nih.gov/pubmed/25819042
478.Yi, T.J., et al. Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized, placebo-controlled crossover trial. J Infect Dis, 2014. 210: 708.
https://www.ncbi.nlm.nih.gov/pubmed/24664172
479.Wald, A., et al. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial. JAMA, 2016. 316: 2495.
https://www.ncbi.nlm.nih.gov/pubmed/27997653
480.Mark, K.E., et al. Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences. Antimicrob Agents Chemother, 2014. 58: 5016.
https://www.ncbi.nlm.nih.gov/pubmed/24709264
481.Khemis, A., et al. Evaluation of the activity and safety of CS21 barrier genital gel® compared to topical aciclovir and placebo in symptoms of genital herpes recurrences: a randomized clinical trial. J Eur Acad Dermatol Venereol, 2014. 28: 1158.
https://www.ncbi.nlm.nih.gov/pubmed/24010876
482.Van Wagoner, N., et al. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. J Infect Dis, 2018. 218: 1890.
https://www.ncbi.nlm.nih.gov/pubmed/29982727
483.Flechtner, J.B., et al. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial. Vaccine, 2016. 34: 5314.
https://www.ncbi.nlm.nih.gov/pubmed/27642130
484.Bernstein, D.I., et al. Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial. J Infect Dis, 2017. 215: 856.
https://www.ncbi.nlm.nih.gov/pubmed/28329211
485.Bernstein, D.I., et al. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. Vaccine, 2019. 37: 3443.
https://www.ncbi.nlm.nih.gov/pubmed/31103365
486.Dropulic, L.K., et al. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. J Infect Dis, 2019. 220: 990.
https://www.ncbi.nlm.nih.gov/pubmed/31058977
487.Chandra, J., et al. Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS One, 2019. 14: e0226320.
https://www.ncbi.nlm.nih.gov/pubmed/31846475
488.Grabowski, M.K., et al. Herpes Simplex [corrected] Virus Type 2 Shedding From Male Circumcision Wounds in Rakai, Uganda. J Infect Dis, 2015. 212: 1613.
https://www.ncbi.nlm.nih.gov/pubmed/25943201
489.Osiecka, B.J., et al. Photodynamic Therapy with Red Light and 5-Aminolaevulinic Acid for Herpes Simplex Recurrence: Preliminary Results. Acta Derm Venereol, 2017. 97: 1239.
https://www.ncbi.nlm.nih.gov/pubmed/28681068
490.Vallely, A.J., et al. Dorsal longitudinal foreskin cut is associated with reduced risk of HIV, syphilis and genital herpes in men: a cross-sectional study in Papua New Guinea. J Int AIDS Soc, 2017. 20: 21358.
https://www.ncbi.nlm.nih.gov/pubmed/28406272
491.Abdool Karim, S.S., et al. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med, 2015. 373: 530.
https://www.ncbi.nlm.nih.gov/pubmed/26244306
492.European Center for Disease Pervention and Control/World Health Organisation. Tuberculosis surveillance and monitoring in Europe 2021 (2019 data). ECDC/WHO. ISBN 978-92-9498-534-7.
https://www.ecdc.europa.eu/sites/default/files/documents/tuberculosis-surveillance-monitoring-Europe-2021.pdf
493.Hayward, S.E., et al. Extrapulmonary tuberculosis among migrants in Europe, 1995 to 2017. Clin Microbiol Infect, 2021. 27: 1347 e1.
https://www.ncbi.nlm.nih.gov/pubmed/33352301
494.Lawn, S.D., et al. Tuberculosis. Lancet, 2011. 378: 57.
https://www.ncbi.nlm.nih.gov/pubmed/21420161
495.Kang, W., et al. Epidemiology of concurrent extrapulmonary tuberculosis in inpatients with extrapulmonary tuberculosis lesions in China: a large-scale observational multi-centre investigation. Int J Infect Dis, 2022. 115: 79.
https://www.ncbi.nlm.nih.gov/pubmed/34781005
496.Vynnycky, E., et al. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect, 1997. 119: 183.
https://www.ncbi.nlm.nih.gov/pubmed/9363017
497.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention - tuberculosis preventive treatment. ISBN 978-92-4-000150-3, 2020.
https://www.who.int/publications/i/item/9789240001503
498.Lewinsohn, D.M., et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis, 2017. 64: 111.
https://www.ncbi.nlm.nih.gov/pubmed/28052967
499.European Centre for Disease Prevention and Control. Mastering the basics of TB control: Development of a handbook on TB diagnostic methods. Stockholm, ECDC, 2011. ISBN 978-92-9193-242-9.
https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/1105_TER_Basics_TB_control.pdf
500.Ye, Y., et al. Clinical Features and Drug-Resistance Profile of Urinary Tuberculosis in South-Western China: A Cross-sectional Study. Medicine (Baltimore), 2016. 95: e3537.
https://www.ncbi.nlm.nih.gov/pubmed/27175652
501.Pingle, P., et al. Evaluation of Microscopy, Culture and PCR Methods in the Laboratory Diagnosis of Genito-urinary Tuberculosis. American Journal of Infectious Diseases and Microbiology, 2014. 2: 17.
http://pubs.sciepub.com/ajidm/2/1/4
502.Sun, L., et al. Rapid diagnosis in early stage renal tuberculosis by real-time polymerase chain reaction on renal biopsy specimens. Int J Tuberc Lung Dis, 2010. 14: 341.
https://www.ncbi.nlm.nih.gov/pubmed/20132626
503.Kumar, P., et al. Diagnosis of renal tuberculosis by real-time polymerase chain reaction in renal biopsy sample. World Journal of Pharmaceutical and Medical Research, 2017. 3: 285.
https://www.wjpmr.com/download/article/25082017/1504230975.pdf
504.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection 2021 update. ISBN 978-92-4-002941-5 2021.
https://www.who.int/publications/i/item/9789240029415
505.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Web Annex 4. Evidence synthesis and analysis. ISBN 978-92-4-001026-0, 2020.
https://iris.who.int/items/e0a34fe0-84b3-4e35-b66a-77c62fc92987
506.Hemal, A.K., et al. Polymerase chain reaction in clinically suspected genitourinary tuberculosis: comparison with intravenous urography, bladder biopsy, and urine acid fast bacilli culture. Urology, 2000. 56: 570.
https://www.ncbi.nlm.nih.gov/pubmed/11018606
507.Muttarak, M., et al. Tuberculous epididymitis and epididymo-orchitis: sonographic appearances. AJR Am J Roentgenol, 2001. 176: 1459.
https://www.ncbi.nlm.nih.gov/pubmed/11373214
508.Yang, D.M., et al. Differential diagnosis of focal epididymal lesions with gray scale sonographic, color Doppler sonographic, and clinical features. J Ultrasound Med, 2003. 22: 135.
https://www.ncbi.nlm.nih.gov/pubmed/12562118
509.Li, S., et al. A better understanding of testicular and/or epididymal tuberculosis based on clinical, ultrasonic, computed tomography, and magnetic resonance imaging features at a high-volume institute in the modern era. Quant Imaging Med Surg, 2021. 11: 2465.
https://www.ncbi.nlm.nih.gov/pubmed/34079716
510.Jing, J., et al. Vas deferens sonographic appearances of tuberculosis lesions of 19 cases of male genital systemic tuberculosis. Medicine (Baltimore), 2019. 98: e14843.
https://www.ncbi.nlm.nih.gov/pubmed/30882677
511.Yang, D.M., et al. Chronic tuberculous epididymitis: color Doppler US findings with histopathologic correlation. Abdom Imaging, 2000. 25: 559.
https://www.ncbi.nlm.nih.gov/pubmed/10931999
512.Rui, X., et al. Ultrasonographic diagnosis and typing of renal tuberculosis. Int J Urol, 2008. 15: 135.
https://www.ncbi.nlm.nih.gov/pubmed/18269447
513.Radwan, A., et al. Multimodality Imaging of Genitourinary Tuberculosis. Curr Probl Diagn Radiol, 2021. 50: 867.
https://www.ncbi.nlm.nih.gov/pubmed/33272721
514.Baumgarten, D.A., et al. Imaging and radiologic management of upper urinary tract infections. Urol Clin North Am, 1997. 24: 545.
https://www.ncbi.nlm.nih.gov/pubmed/9275978
515.Muttarak, M., et al. Tuberculosis of the genitourinary tract: imaging features with pathological correlation. Singapore Med J, 2005. 46: 568.
https://www.ncbi.nlm.nih.gov/pubmed/16172781
516.Wang, Y., et al. Computerised tomography and intravenous pyelography in urinary tuberculosis: a retrospective descriptive study. Int J Tuberc Lung Dis, 2015. 19: 1441.
https://www.ncbi.nlm.nih.gov/pubmed/26614184
517.Sataa, S., et al. Imaging findings of urinary tuberculosis on computerized tomography versus excretory urography: Through 46 confirmed cases. Tunisie Medicale, 2014. 92: 743.
https://www.ncbi.nlm.nih.gov/pubmed/25879600
518.Wang, L.J., et al. Imaging findings of urinary tuberculosis on excretory urography and computerized tomography. J Urol, 2003. 169: 524.
https://www.ncbi.nlm.nih.gov/pubmed/12544301
519.Birnbaum, B.A., et al. Extrarenal genitourinary tuberculosis: CT appearance of calcified pipe-stem ureter and seminal vesicle abscess. J Comput Assist Tomogr, 1990. 14: 653.
https://www.ncbi.nlm.nih.gov/pubmed/2370364
520.Jung, Y.Y., et al. Genitourinary tuberculosis: comprehensive cross-sectional imaging. AJR Am J Roentgenol, 2005. 184: 143.
https://www.ncbi.nlm.nih.gov/pubmed/15615965
521.Wang, L.J., et al. CT features of genitourinary tuberculosis. J Comput Assist Tomogr, 1997. 21: 254.
https://www.ncbi.nlm.nih.gov/pubmed/9071295
522.Sharma, J.B., et al. Female genital tuberculosis: Revisited. Indian J Med Res, 2018. 148: S71.
https://www.ncbi.nlm.nih.gov/pubmed/30964083
523.Mantica, G., et al. Genitourinary Tuberculosis: A Comprehensive Review of a Neglected Manifestation in Low-Endemic Countries. Antibiotics (Basel), 2021. 10.
https://www.ncbi.nlm.nih.gov/pubmed/34827337
524.da Rocha, E.L., et al. Abdominal tuberculosis: a radiological review with emphasis on computed tomography and magnetic resonance imaging findings. Radiol Bras, 2015. 48: 181.
https://www.ncbi.nlm.nih.gov/pubmed/26185345
525.Cheng, Y., et al. Multiparametric Magnetic Resonance Imaging Characteristics of Prostate Tuberculosis. Korean J Radiol, 2015. 16: 846.
https://www.ncbi.nlm.nih.gov/pubmed/26175584
526.Ahmadi, F., et al. Hysterosalpingographic Appearances of Female Genital Tract Tuberculosis: Part II: Uterus. Int J Fertil Steril, 2014. 8: 13.
https://www.ncbi.nlm.nih.gov/pubmed/24696765
527.Ahmadi, F., et al. Hysterosalpingographic appearances of female genital tract tuberculosis: part I. Fallopian tube. Int J Fertil Steril, 2014. 7: 245.
https://www.ncbi.nlm.nih.gov/pubmed/24520493
528.Netter, A., et al. [Tuberculous endo-uterine symphysis; an anatomo-clinical and radiologically characteristic syndrome]. Gynecol Obstet (Paris), 1955. 54: 19.
https://www.ncbi.nlm.nih.gov/pubmed/14391756
529.World Health Organization. WHO consolidated guidelines on tuberculosis Module 4: Treatment: Drug-susceptible tuberculosis treatment 2022. ISBN 978-92-4-004812-6.
https://www.who.int/publications/i/item/9789240048126
530.European Centre for Disease Pervention and Control. European Union Standards for Tuberculosis Care 2017 update. ISBN 978-92-9498-247-6.
https://www.ecdc.europa.eu/en/publications-data/european-union-standards-tuberculosis-care-2017-update
531.Huang, Y., et al. Surgical management of tuberculous epididymo-orchitis: a retrospective study of 81 cases with long-term follow-up. BMC Infect Dis, 2021. 21: 1068.
https://www.ncbi.nlm.nih.gov/pubmed/34654377
532.Mittal, A., et al. Surgical Management of Genitourinary Tuberculosis: our Experience and review of literature. Pol Przegl Chir, 2020. 92: 1.
https://www.ncbi.nlm.nih.gov/pubmed/33408264
533.Figueiredo, A.A., et al. Epidemiology of urogenital tuberculosis worldwide. Int J Urol, 2008. 15: 827.
https://www.ncbi.nlm.nih.gov/pubmed/18637157
534.Mochalova, T.P., et al. Reconstructive surgery for treatment of urogenital tuberculosis: 30 years of observation. World J Surg, 1997. 21: 511.
https://www.ncbi.nlm.nih.gov/pubmed/9204739
535.Gupta, N.P., et al. Reconstructive surgery for the management of genitourinary tuberculosis: a single center experience. J Urol, 2006. 175: 2150.
https://www.ncbi.nlm.nih.gov/pubmed/16697825
536.Kumar, A., et al. Can kidneys be saved in patients with urinary tuberculosis? A study in the era of modern chemotherapy and surgical armamentarium. Int J Urol, 2019. 26: 551.
https://www.ncbi.nlm.nih.gov/pubmed/30803052
537.Pal, D.K., et al. Role of surgical intervention in genitourinary tuberculosis in the era of modern anti-tubercular chemotherapy. Sch. J. App. Med. Sci, 2015. 3: 1608.
https://www.researchgate.net/publication/279925411
538.Li, X., et al. A Clinical Comparative Analysis of Retroperitoneal Laparoscopic Tuberculous Nephrectomy and Open Tuberculous Nephrectomy. J Laparoendosc Adv Surg Tech A, 2019. 29: 909.
https://www.ncbi.nlm.nih.gov/pubmed/30932738
539.Zhang, S., et al. Open surgery versus retroperitoneal laparoscopic nephrectomy for renal tuberculosis: a retrospective study of 120 patients. PeerJ, 2016. 4: e2708.
https://www.ncbi.nlm.nih.gov/pubmed/27917313
540.Kim, H.H., et al. Laparoscopic nephrectomy for nonfunctioning tuberculous kidney. J Endourol, 2000. 14: 433.
https://www.ncbi.nlm.nih.gov/pubmed/10958566
541.Han, W.K., et al. The feasibility of laparoendoscopic single-site nephrectomy: initial experience using home-made single-port device. Urology, 2010. 76: 862.
https://www.ncbi.nlm.nih.gov/pubmed/20110116
542.Hemal, A.K., et al. Comparison of retroperitoneoscopic nephrectomy with open surgery for tuberculous nonfunctioning kidneys. J Urol, 2000. 164: 32.
https://www.ncbi.nlm.nih.gov/pubmed/10840418
543.Kauffman, C.A., et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis, 2000. 30: 14.
https://www.ncbi.nlm.nih.gov/pubmed/10619726
544.Ahmadikia, K., et al. Increased urine Interleukin-17 and Interleukin-22 levels in patients with candidal urinary tract infection. Iran J Kidney Dis, 2018. 12: 33EP.
https://pubmed.ncbi.nlm.nih.gov/29421775
545.Fisher, J.F. Candida urinary tract infections--epidemiology, pathogenesis, diagnosis, and treatment: executive summary. Clin Infect Dis, 2011. 52 Suppl 6: S429.
https://www.ncbi.nlm.nih.gov/pubmed/21498835
546.Konje, E.T., et al. Five-year cross-sectional study to determine the burden of Candida spp. infections of the urinary tract system among patients attending tertiary hospital in Northwestern Tanzania. BMJ open, 2023. 13: e074833.
https://pubmed.ncbi.nlm.nih.gov/38154909
547.Bouza, E., et al. A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections. Clin Microbiol Infect, 2001. 7: 523.
https://www.ncbi.nlm.nih.gov/pubmed/11683792
548.Alvarez-Lerma, F., et al. Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med, 2003. 29: 1069.
https://www.ncbi.nlm.nih.gov/pubmed/12756441
549.Alvarez-Lerma, F., et al. [Fungal colonization and/or infection in intensive care units. Multicenter study of 1,562 patients]. Med Clin (Barc), 2003. 121: 161.
https://www.ncbi.nlm.nih.gov/pubmed/12867000
550.Kumar, R., et al. Prevalence of Candida species in Urinary Tract Infections from a Tertiary Care Hospital Prospective study. International Journal of Life Sciences Biotechnology and Pharma Research, 2024. 13: 671.
https://ijlbpr.com/uploadfiles/122vol13issue3pp671-672.20240716063122.pdf
551.Centers for Disease Control and Prevention. About C. auris. 2024.
https://www.cdc.gov/candida-auris/about/index.html
552.Chowdhary, A., et al. Candida auris Genetics and Emergence. Annu Rev Microbiol, 2023. 77: 583.
https://www.ncbi.nlm.nih.gov/pubmed/37406342
553.Griffith, N., et al. Candida auris Urinary Tract Infections and Possible Treatment. Antibiotics (Basel), 2020. 9.
https://www.ncbi.nlm.nih.gov/pubmed/33322761
554.Krcmery, S., et al. Fungal urinary tract infections in patients at risk. International journal of antimicrobial agents, 1999. 11: 289.
https://www.ncbi.nlm.nih.gov/pubmed/10394985
555.Kamani, L., et al. Fungal urinary tract infection among chronic liver disease patients with hepatic encephalopathy and its treatment outcomes. JGH Open, 2021. 5: 213.
https://pubmed.ncbi.nlm.nih.gov/33553658
556.Rashwan, N.M., et al. Pattern of candida urinary tract infections among cancer patients in South Egypt Cancer Institute. Bulletin of Pharmaceutical Sciences, 2010. 33: 121.
https://bpsa.journals.ekb.eg/article_147033.html
557.Sarwar, F., et al. Fungal Urinary Tract Infection; A Study Conducted on Patients with Liver Cirrhosis. Pakistan Journal of Medical and Health Sciences, 2021. 15: 3129.
http://pjmhsonline.com/published-issues/2021/november/113129
558.Chen, L.F., et al. Hospital-acquired urinary tract infections in patients with diabetes and urinary catheterization. Journal of Experimental and Clinical Medicine (Taiwan), 2014. 6: 90.
https://hub.tmu.edu.tw/en/publications/hospital-acquired-urinary-tract-infections-in-patients-with-diabe/
559.Deorukhkar, S.C., et al. Medical Device-Associated Candida Infections in a Rural Tertiary Care Teaching Hospital of India. Interdiscip Perspect Infect Dis, 2016. 2016: 1854673.
https://pubmed.ncbi.nlm.nih.gov/26904115
560.Karthikeya, P., et al. Urinary Tract Infections In Catheterized Patients And Antibiotic Sensitivity Patterns. European Journal of Molecular and Clinical Medicine, 2022. 9: 1200.
https://www.ejmcm.com/archives/volume-9/issue-1/1161
561.Clifford, T.G., et al. Urinary tract infections following radical cystectomy and urinary diversion: a review of 1133 patients. World J Urol, 2018. 36: 775.
https://pubmed.ncbi.nlm.nih.gov/29372354
562.Lu, X., et al. Early Warning Models to Predict the 90-Day Urinary Tract Infection Risk After Radical Cystectomy and Urinary Diversion for Patients With Bladder Cancer. Front Surg, 2021. 8: 782029.
https://pubmed.ncbi.nlm.nih.gov/35127802
563.Jensen, J.U., et al. Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime. Crit Care Med, 2015. 43: 594.
https://www.ncbi.nlm.nih.gov/pubmed/25493970
564.Kauffman, C.A. Candiduria. Clin Infect Dis, 2005. 41 Suppl 6: S371.
https://www.ncbi.nlm.nih.gov/pubmed/16108001
565.Kauffman, C.A., et al. Candida urinary tract infections--diagnosis. Clin Infect Dis, 2011. 52 Suppl 6: S452.
https://www.ncbi.nlm.nih.gov/pubmed/21498838
566.de Freitas, A.R., et al. Yeasts isolated from nosocomial urinary infections: Antifungal susceptibility and biofilm production. Rev Iberoam Micol, 2014. 31: 104EP.
https://pubmed.ncbi.nlm.nih.gov/23810785
567.Kauffman, C.A. Diagnosis and management of fungal urinary tract infection. Infect Dis Clin North Am, 2014. 28: 61.
https://www.ncbi.nlm.nih.gov/pubmed/24484575
568.Jacobs, L.G., et al. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis, 1996. 22: 30.
https://pubmed.ncbi.nlm.nih.gov/8824962
569.Jacobs, L.G., et al. Bladder irrigation with amphotericin B for treatment of fungal urinary tract infections. Clin Infect Dis, 1994. 18: 313.
https://pubmed.ncbi.nlm.nih.gov/8011810
570.Gabardi, S., et al. Micafungin treatment and eradication of candiduria among hospitalized patients. Int Urol Nephrol, 2016. 48: 1881.
https://pubmed.ncbi.nlm.nih.gov/27587066
571.de Vasconcelos, A.A., Jr., et al. Chromogenic medium for direct susceptibility testing of Candida spp. isolated from urine. Mycopathologia, 2011. 172: 125.
https://www.ncbi.nlm.nih.gov/pubmed/21369747
572.Nicolle, L.E. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging, 2001. 18: 243.
https://www.ncbi.nlm.nih.gov/pubmed/11341472
573.Wise, G.J. Genitourinary fungal infections: a therapeutic conundrum. Expert Opin Pharmacother, 2001. 2: 1211.
https://www.ncbi.nlm.nih.gov/pubmed/11584989
574.Sadegi, B.J., et al. Primary renal candidiasis: importance of imaging and clinical history in diagnosis and management. J Ultrasound Med, 2009. 28: 507.
https://www.ncbi.nlm.nih.gov/pubmed/19321678
575.Erden, A., et al. Radiological findings in the diagnosis of genitourinary candidiasis. Pediatr Radiol, 2000. 30: 875.
https://www.ncbi.nlm.nih.gov/pubmed/11149100
576.Pappas, P.G., et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2016. 62: e1.
https://www.ncbi.nlm.nih.gov/pubmed/26679628
577.Sobel, J.D., et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis, 2000. 30: 19.
https://www.ncbi.nlm.nih.gov/pubmed/10619727
578.Potasman, I., et al. Oral fluconazole for Candida urinary tract infection. Urol Int, 1997. 59: 252.
https://pubmed.ncbi.nlm.nih.gov/9444745
579.Bell, D.A., et al. Percutaneous nephrostomy for nonoperative management of fungal urinary tract infections. Journal of vascular and interventional radiology : JVIR, 1993. 4: 311.
https://www.ncbi.nlm.nih.gov/pubmed/8481584
580.Wise, G.J., et al. Flucytosine in urinary candida infections. Urology, 1974. 3: 708EP.
https://www.goldjournal.net/article/S0090-4295(74)80209-8/abstract
581.Fan, X., et al. High prevalence of fluconazole resistant Candida tropicalis among candiduria samples in China: An ignored matter of concern. Front Microbiol, 2023. 14: 1125241.
https://www.ncbi.nlm.nih.gov/pubmed/36937265
582.Sobel, J.D., et al. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis, 2007. 44: e46.
https://www.ncbi.nlm.nih.gov/pubmed/17278048
583.Rkieh, L., et al. Outcomes of caspofungin use in the treatment of Candida-related urinary tract infections, a case series. IDCases, 2022. 28: e01510.
https://pubmed.ncbi.nlm.nih.gov/35646592
584.Grau, S., et al. Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp. Int J Antimicrob Agents, 2016. 48: 212.
https://www.ncbi.nlm.nih.gov/pubmed/27424599
585.Govel, J.C., et al. Evaluation of shorter versus longer antifungal treatment durations for Candida spp. urinary tract infections among hospitalized adults. Antimicrob Agents Chemother, 2025. 69: e0192024.
https://pubmed.ncbi.nlm.nih.gov/40261002
586.Graybill, J.R., et al. Ketoconazole therapy for fungal urinary tract infections. J Urol, 1983. 129: 68EP.
https://pubmed.ncbi.nlm.nih.gov/6298476
587.Boglione-Kerrien, C., et al. Voriconazole as an alternative oral treatment in fluconazole-resistant urinary candidiasis. Infect Dis Now, 2024. 54: 104955.
https://pubmed.ncbi.nlm.nih.gov/39043250
588.Zeitoun, H., et al. Elucidation of the mechanisms of fluconazole resistance and repurposing treatment options against urinary Candida spp. isolated from hospitalized patients in Alexandria, Egypt. BMC Microbiol, 2024. 24: 383.
https://pubmed.ncbi.nlm.nih.gov/39354378
589.Tuon, F.F., et al. Bladder irrigation with amphotericin B and fungal urinary tract infection--systematic review with meta-analysis. Int J Infect Dis, 2009. 13: 701.
https://www.ncbi.nlm.nih.gov/pubmed/19155184
590.Puckrin, R., et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol, 2018. 55: 503.
https://www.ncbi.nlm.nih.gov/pubmed/29484489
591.Ren, J., et al. Sodium-glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta-analysis. Br J Clin Pharmacol, 2025. 91: 2621.
https://www.ncbi.nlm.nih.gov/pubmed/40289746
592.Li, D., et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab, 2017. 19: 348.
https://www.ncbi.nlm.nih.gov/pubmed/27862830
593.Guo, M., et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine, 2020. 67: 294.
https://pubmed.ncbi.nlm.nih.gov/31900793
594.Lega, I.C., et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes, Obesity and Metabolism, 2019. 21: 2394.
https://pubmed.ncbi.nlm.nih.gov/31264755/
595.Chan, G.C.K., et al. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study. Diabetes Res Clin Pract, 2023. 195: 110200.
https://pubmed.ncbi.nlm.nih.gov/36481225
596.Xu, J., et al. Risk of Urinary Tract Infections with Sodium-Glucose Transport Protein-2 Inhibitors in Subpopulations with Abnormal Genitourinary Pathology. Clin J Am Soc Nephrol, 2025. 20: 820EP.
https://pubmed.ncbi.nlm.nih.gov/40215113
597.European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 - Healthcare-associated infections acquired in intensive care units. 2016.
https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-intensive-care-units-annual-epidemiological-0
598.Control, C.f.D. Procedure-associated Module 9: Surgical Site Infection (SSI) Event. . 2017.
https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf
599.Tanner, J., et al. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev, 2016. 2016: CD004288.
https://www.ncbi.nlm.nih.gov/pubmed/26799160
600.Webster, J., et al. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev, 2015. 2015: CD004985.
https://www.ncbi.nlm.nih.gov/pubmed/25927093
601.Tanner, J., et al. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev, 2011: CD004122.
https://www.ncbi.nlm.nih.gov/pubmed/22071812
602.Arnold, A., et al. Preoperative Mechanical Bowel Preparation for Abdominal, Laparoscopic, and Vaginal Surgery: A Systematic Review. J Minim Invasive Gynecol, 2015. 22: 737.
https://www.ncbi.nlm.nih.gov/pubmed/25881881
603.Guenaga, K.F., et al. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev, 2011. 2011: CD001544.
https://www.ncbi.nlm.nih.gov/pubmed/21901677
604.Dumville, J.C., et al. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev, 2015. 2015: CD003949.
https://www.ncbi.nlm.nih.gov/pubmed/25897764
605.Webster, J., et al. Use of plastic adhesive drapes during surgery for preventing surgical site infection. Cochrane Database Syst Rev, 2015. 2015: CD006353.
https://www.ncbi.nlm.nih.gov/pubmed/25901509
606.Bonkat, G., et al. Non-molecular Methods to Detect Bacteriuria Prior to Urological Interventions: A Diagnostic Accuracy Systematic Review. Eur Urol Focus, 2017. 3: 535.
https://www.ncbi.nlm.nih.gov/pubmed/29627196
607.European Centre for Disease Prevention and Control. Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis. 2013.
https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Perioperative%20antibiotic%20prophylaxis%20-%20June%202013.pdf
608.Antibacterial prophylaxis in surgery. Drug and Therapeutics Bulletin, 2004. 42: 9.
https://dtb.bmj.com/content/42/2/9.2
609.Benseler, A., et al. Antibiotic prophylaxis for urodynamic testing in women: a systematic review. Int Urogynecol J, 2021. 32: 27.
https://www.ncbi.nlm.nih.gov/pubmed/32845398
610.Foon, R., et al. Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies [Systematic Review]. Cochrane Database of Systematic Reviews, 2012. 10: 10.
https://pubmed.ncbi.nlm.nih.gov/23076941/
611.Carey, M.M., et al. Should We Use Antibiotic Prophylaxis for Flexible Cystoscopy? A Systematic Review and Meta-Analysis. Urol Int, 2015. 95: 249.
https://www.ncbi.nlm.nih.gov/pubmed/26138144
612.Garcia-Perdomo, H.A., et al. Efficacy of antibiotic prophylaxis in cystoscopy to prevent urinary tract infection: a systematic review and meta-analysis. Int Braz J Urol, 2015. 41: 412.
https://www.ncbi.nlm.nih.gov/pubmed/26200530
613.Zeng, S., et al. Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy. Cochrane Database Syst Rev, 2019. 2: CD012305.
https://www.ncbi.nlm.nih.gov/pubmed/30789676
614.Bradshaw, A.W., et al. Antibiotics are not necessary during routine cystoscopic stent removal: A randomized controlled trial at UC San Diego. Urol Ann, 2020. 12: 373.
https://www.ncbi.nlm.nih.gov/pubmed/33776335
615.Lu, Y., et al. Antibiotic prophylaxis for shock wave lithotripsy in patients with sterile urine before treatment may be unnecessary: a systematic review and meta-analysis. J Urol, 2012. 188: 441.
https://www.ncbi.nlm.nih.gov/pubmed/22704118
616.Mrkobrada, M., et al. CUA Guidelines on antibiotic prophylaxis for urologic procedures. Can Urol Assoc J, 2015. 9: 13.
https://www.ncbi.nlm.nih.gov/pubmed/25737749
617.Hsieh, C.H., et al. The Effectiveness of Prophylactic Antibiotics with Oral Levofloxacin against Post-Shock Wave Lithotripsy Infectious Complications: A Randomized Controlled Trial. Surg Infect (Larchmt), 2016. 17: 346.
https://www.ncbi.nlm.nih.gov/pubmed/26910613
618.Shafi, H., et al. Antibiotic prophylaxis in the prevention of urinary tract infection in patients with sterile urine before extracorporeal shock wave lithotripsy. Caspian J Intern Med, 2018. 9: 296.
https://www.ncbi.nlm.nih.gov/pubmed/30197776
619.Lin, H.Y., et al. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naive Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Int J Neuropsychopharmacol, 2015. 19: pyv094.
https://www.ncbi.nlm.nih.gov/pubmed/26377368
620.Tikkinen, K.A.O., et al. A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections after Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial. Eur Urol, 2025. 88: 543.
https://www.ncbi.nlm.nih.gov/pubmed/40998628
621.Deng, T., et al. Antibiotic prophylaxis in ureteroscopic lithotripsy: a systematic review and meta-analysis of comparative studies. BJU Int, 2018. 122: 29.
https://www.ncbi.nlm.nih.gov/pubmed/29232047
622.Zhao, Z., et al. Recommended antibiotic prophylaxis regimen in retrograde intrarenal surgery: evidence from a randomised controlled trial. BJU Int, 2019. 124: 496.
https://www.ncbi.nlm.nih.gov/pubmed/31136070
623.Qiao, L.D., et al. Evaluation of perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal: an investigator-driven prospective, multicenter, randomized, controlled study. Int Urol Nephrol, 2018. 50: 427.
https://www.ncbi.nlm.nih.gov/pubmed/29290000
624.Yu, J., et al. Antibiotic prophylaxis in perioperative period of percutaneous nephrolithotomy: a systematic review and meta-analysis of comparative studies. World J Urol, 2020. 38: 1685.
https://www.ncbi.nlm.nih.gov/pubmed/31562533
625.Seyrek, M., et al. Perioperative prophylaxis for percutaneous nephrolithotomy: randomized study concerning the drug and dosage. J Endourol, 2012. 26: 1431.
https://www.ncbi.nlm.nih.gov/pubmed/22612061
626.Tuzel, E., et al. Prospective comparative study of two protocols of antibiotic prophylaxis in percutaneous nephrolithotomy. J Endourol, 2013. 27: 172.
https://www.ncbi.nlm.nih.gov/pubmed/22908891
627.Omar, M., et al. Ciprofloxacin infusion versus third generation cephalosporin as a surgical prophylaxis for percutaneous nephrolithotomy: a randomized study. Cent European J Urol, 2019. 72: 57.
https://www.ncbi.nlm.nih.gov/pubmed/31011442
628.Taken, K., et al. Comparison of Ceftriaxone and Cefazolin Sodium Antibiotic Prophylaxis in Terms of SIRS/Urosepsis Rates in Patients Undergoing Percutaneous Nephrolithotomy. J Urol Surg, 2019. 6: 111.
https://jurolsurgery.org/articles/comparison-of-ceftriaxone-and-cefazolin-sodium-antibiotic-prophylaxis-in-terms-of-sirsurosepsis-rates-in-patients-undergoing-percutaneous-nephrolithotomy/doi/jus.galenos.2018.2367
629.Dahm, P., et al. Evidence-based Urology. BMJ Books London, 2010: 50.
630.Bausch, K., et al. Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-Analysis. J Urol, 2021. 205: 987.
https://www.ncbi.nlm.nih.gov/pubmed/33284673
631.Yang, J., et al. Prospective, randomized controlled study of the preventive effect of fosfomycin tromethamine on post-transurethral resection of bladder tumor urinary tract infection. Int J Urol, 2018. 25: 894.
https://www.ncbi.nlm.nih.gov/pubmed/29999216
632.Sanaee, M.S., et al. Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: A systematic review and meta-analysis. Acta Obstet Gynecol Scand, 2019. 98: 1514.
https://www.ncbi.nlm.nih.gov/pubmed/31112286
633.Crawford, D., et al. Infectious Outcomes from Renal Tumor Ablation: Prophylactic Antibiotics or Not? Cardiovasc Intervent Radiol, 2018. 41: 1573.
https://www.ncbi.nlm.nih.gov/pubmed/30062444
634.Ploussard, G., et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). European Urology Oncology, 2024. 7: 1080.
https://www.sciencedirect.com/science/article/pii/S258893112400049X
635.Mian, B.M., et al. Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial. J Urol, 2024. 211: 205.
https://pubmed.ncbi.nlm.nih.gov/37976319
636.Hu, J.C., et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol, 2024. 86: 61.
https://www.ncbi.nlm.nih.gov/pubmed/38212178
637.Hu, J.C., et al. Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial. JAMA Oncology, 2024. 10: 1590.
https://pubmed.ncbi.nlm.nih.gov/39298143/
638.Bryant, R.J., et al. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. The lancet. Oncology, 2025. 26: 583.
https://pubmed.ncbi.nlm.nih.gov/40139210
639.Tricard, T., et al. Transperineal MRI-guided Prostate Biopsy: a Prospective Randomized Controlled Study on Safety and Efficacy. Journal of vascular and interventional radiology: JVIR, 2025.
https://pubmed.ncbi.nlm.nih.gov/40389061/
640.Pradere, B., et al. Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol, 2021. 205: 653.
https://www.ncbi.nlm.nih.gov/pubmed/33026903
641.Lam, W., et al. Abstracts of the Hong Kong Urological Association 26th Annual Scientific Meeting, Hong Kong, 17 October 2021. BJU Int, 2022. 129 Suppl 1: 4.
https://www.ncbi.nlm.nih.gov/pubmed/35202507
642.Stangl, F.P., et al. Infectious Complications After Transrectal Versus Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Focus, 2025.
https://www.ncbi.nlm.nih.gov/pubmed/40774844
643.Bennett, H.Y., et al. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect, 2016. 144: 1784.
https://www.ncbi.nlm.nih.gov/pubmed/26645476
644.Berry, B., et al. Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. BJU Int, 2020. 126: 97.
https://www.ncbi.nlm.nih.gov/pubmed/32124525
645.Mian, B.M., et al. Reply: complications Following Transrectal and Transperineal Prostate Biopsy: results of the ProBE-PC Randomized Clinical Trial. J Urol, 2024. 212: 227.
https://pubmed.ncbi.nlm.nih.gov/38728260/
646.Hu, J.C., et al. Transperineal vs Transrectal Prostate Biopsy-The PREVENT Randomized Clinical Trial. JAMA Oncol, 2024. 10: 1590.
https://www.ncbi.nlm.nih.gov/pubmed/39298143
647.Wolff, I., et al. Infectious complications following transperineal prostate biopsy with or without periprocedural antibiotic prophylaxis-a systematic review including meta-analysis of all comparative studies. Prostate Cancer and Prostatic Dis, 2025: 94.
https://pubmed.ncbi.nlm.nih.gov/39741175
648.Basourakos, S.P., et al. Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Open Sci, 2022. 37: 53.
https://www.ncbi.nlm.nih.gov/pubmed/35243391
649.Chernysheva, D.Y., et al. The first experience of transperineal prostate biopsy without antibiotic prophylaxis. Cancer Urology, 2021. 17: 46.
https://www.researchgate.net/publication/353446695
650.Jacewicz, M., et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis, 2022. 22: 1465.
https://www.ncbi.nlm.nih.gov/pubmed/35839791
651.Shaker, H.S., et al. Does The Use Of Povidone Iodine Suppository Decrease The Infective Complications Of TRUS Guided Prostate Biopsies? A Randomized Prospective Study. QJM: An International Journal of Medicine, 2020. 113.
https://academic.oup.com/qjmed/article-abstract/113/Supplement_1/hcaa070.024/5829649?redirectedFrom=fulltext
652.Ergani, B., et al. Effect of rectal mucosa cleansing on acute prostatitis during prostate biopsy: A randomized prospective study. Turk J Urol, 2020. 46: 159.
https://www.ncbi.nlm.nih.gov/pubmed/31922485
653.Farooq, K., et al. Role of Povidone-Iodine-Soaked Gauze in Preventing Infectious Complications Following Trans Rectal Digital Guided Prostate Biopsy. Journal of Postgraduate Medical Institute, 2021. 35: 225.
https://jpmi.org.pk/index.php/jpmi/article/view/2849
654.Cetin, T., et al. Saline cleansing can prevent infective complications after transrectal prostate biopsy: A randomized prospective study. Urologia Journal, 2024. 91: 768
https://pubmed.ncbi.nlm.nih.gov/39212152/
655.Taher, Y., et al. (2014) Prospective randomized controlled study to assess the effect of perineal region cleansing with povidone iodine before transrectal needle biopsy of the prostate on infectious complications. Urology 84, S306.
https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01023606/full
656.Yu, L., et al. [Impact of insertion timing of iodophor cotton ball on the control of infection complications after transrectal ultrasound guided prostate biopsy]. Zhonghua Yi Xue Za Zhi, 2014. 94: 609.
https://www.ncbi.nlm.nih.gov/pubmed/24762693
657.Ezenwa, E.V., et al. Apical peri-prostatic nerve block versus intra-rectal xylocaine gel for trans- rectal ultrasound guided prostate biopsy among Nigerian patients: A prospective randomized study. Niger J Clin Pract, 2020. 23: 1183.
https://www.ncbi.nlm.nih.gov/pubmed/32913154
658.Jang, H., et al. Comparison of intrarectal heated lidocaine gel and periprostatic nerve block for pain control in transrectal ultrasound-guided prostate biopsy: A randomized controlled non-inferiority trial. Prostate Int, 2023. 11: 8.
https://www.ncbi.nlm.nih.gov/pubmed/36910899
659.Russo, F., et al. MR-tergeted vs. TRUS-guided prostate biopsy in patients with high PSA values: A randomizied controlled trial. Anticancer Research, 2016. 36: 2556.
https://ar.iiarjournals.org/content/anticanres/36/5/2535.full.pdf
660.Pilatz, A., et al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol, 2020. 204: 224.
https://www.ncbi.nlm.nih.gov/pubmed/32105195
661.Bouzouita, A., et al. Antimicrobial prophylaxis protocol based on rectal swab culture before prostate biopsy to prevent infectious complications: a prospective randomized comparative study. Int Urol Nephrol, 2024. 56: 2495.
https://www.ncbi.nlm.nih.gov/pubmed/38448785
662.Sadahira, T., et al. Significance of Targeted Antimicrobial Prophylaxis Using Rectal-culture Selective Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial. Urology, 2025. 196: 32.
https://pubmed.ncbi.nlm.nih.gov/39694101
663.Supreeth, N., et al. Prospective randomized controlled study of comparing efficacy of prophylactic intraprostatic antibiotic injection with oral antibiotic verses standard oral prophylaxis in patients undergoing transrectal ultrasonography guided prostate biopsy. Indian Journal of Urology, 2023. 39: S3.
664.Andreasson, A., et al. Fosfomycin versus Ciprofloxacin as transrectal prostatebiopsy antibiotic prophylaxis - an open randomized controlled multicenter drug trial. Eur Urol, 2023. 83: S180.
https://www.sciencedirect.com/science/article/abs/pii/S0302283823001835
665.Feher, A.M., et al. Single-dose vs prolonged antibiotic prophylaxis of fosfomycin for transrectal prostate biopsy: a single-center prospective, randomized, controlled trial. Prostate International, 2025. 13: 28
https://pubmed.ncbi.nlm.nih.gov/40213351/
666.Carignan, A., et al. Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: Results from a large Canadian cohort. J Glob Antimicrob Resist, 2019. 17: 112.
https://www.ncbi.nlm.nih.gov/pubmed/30553114
667.Pilatz, A., et al. European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy. Eur Urol, 2021. 79: 11.
https://www.ncbi.nlm.nih.gov/pubmed/33172721